

CITATION REPORT

List of articles citing

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

DOI: 10.1176/appi.ajp.163.1.28

American Journal of Psychiatry, 2006, 163, 28-40.

Source: <https://exaly.com/paper-pdf/41125774/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2251	Bupropion: pharmacology and therapeutic applications. 2006 , 6, 1249-65		198
2250	After the failure of citalopram for depression, what next?. 2006 , 7, 1515-8		2
2249	Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 2006 , 354, 1231-42		778
2248	Closing the antidepressant efficacy gap between clinical trials and real patient populations. 2006 , 10 Suppl 3, 25-31		1
2247	Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. 2006 , 78, 804-814		396
2246	A review of antidepressant treatments today. 2006 , 16, S619-S623		43
2245	Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. 2006 , 59, 1029-38		102
2244	Triple reuptake inhibitors as antidepressants. 2006 , 3, 489-494		10
2243	Adolescent depression: challenges and opportunities: a review and current recommendations for clinical practice. 2006 , 53, 111-63		17
2242	Initial rate of improvement in major depression. 2006 , 189, 189; author reply 189-90		1
2241	Jordan W. Smoller, MD, ScD. 2006 , 11, 5-7		
2240	Ask the Expert Psychopharmacology: Major depressive disorder. 2006 , 4, 484-486		
2239	STAR*D: The Results Begin to Roll in. 2006 , 4, 525-527		
2238	Beyond efficacy and effectiveness: A multifaceted approach to treatment evaluation.. 2006 , 37, 389-397		35
2237	Remission Rates for Depression in STAR*D Study. <i>American Journal of Psychiatry</i> , 2006 , 163, 1293-1293	11.9	5
2236	STAR*D: The Results Begin to Roll in. <i>American Journal of Psychiatry</i> , 2006 , 163, 1123-1123	11.9	9
2235	A scale to screen for DSM-IV Axis I disorders in psychiatric out-patients: performance of the Psychiatric Diagnostic Screening Questionnaire. 2006 , 36, 1601-11		62

2234	Keeping our eyes on STAR*D. <i>American Journal of Psychiatry</i> , 2006 , 163, 1484-6	11.9	6
2233	Tranlycypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1531-41; quiz 1666	11.9	244
2232	A note on the partnership between psychiatry and primary care. <i>American Journal of Psychiatry</i> , 2006 , 163, 1487-9	11.9	12
2231	The STAR*D study: a four-course meal that leaves us wanting more. <i>American Journal of Psychiatry</i> , 2006 , 163, 1864-6	11.9	35
2230	Dr. Trivedi and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006 , 163, 1293-1294	11.9	4
2229	Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. 2006 , 68, 645-50		121
2228	Recent evidence linking coronary heart disease and depression. 2006 , 51, 730-7		149
2227	Transdermal selegiline: the new generation of monoamine oxidase inhibitors. 2006 , 11, 363-75		54
2226	Recurrent depression: patient characteristics, clinical course, and current recommendations for management. 2006 , 11, 6-11		26
2225	Table of Contents. 2006 , 17, 1-8		
2224	Improving depression care in patients with diabetes and multiple complications. 2006 , 21, 1036-41		44
2223	Cure therapeutics and strategic prevention: raising the bar for mental health research. 2006 , 11, 11-7		208
2222	Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. 2006 , 32, 121-6		50
2221	Major depressive disorder and medical illness: STAR*D outcomes. 2006 , 8, 165-6		1
2220	Clinical differences among patients treated for mental health problems in general medical and specialty mental health settings in the National Comorbidity Survey Replication. 2006 , 28, 387-95		31
2219	Animal models of depression in drug discovery: a historical perspective. 2006 , 84, 436-52		159
2218	The use of psychiatric medications to treat depressive disorders in African American women. 2006 , 62, 793-800		14
2217	Curiosity and crisis. 2006 , 75, 199-201		14

2216	Bipolar disorder treatment: an evidence-based reality check. <i>American Journal of Psychiatry</i> , 2006 , 163, 175-6	11.9	16
2215	Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. 2006 , 40, 2115-22		91
2214	Remissions in maternal depression and child psychopathology: a STAR*D-child report. 2006 , 295, 1389-98		442
2213	One size fits all?. 2006 , 174, 1133-1134		1
2212	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1161-1172	11.9	203
2211	Treatment strategies after SSRI failure--good news and bad news. 2006 , 354, 1305-7		17
2210	Depression--augmentation or switch after initial SSRI treatment. 2006 , 354, 2611-3; author reply 2611-3		8
2209	Report by the ACNP Task Force on response and remission in major depressive disorder. 2006 , 31, 1841-53		469
2208	Citalopram and suicidality in adult major depression and anxiety disorders. 2006 , 60, 392-9		4
2207	Reproductive ageing, sex steroids and depression. 2006 , 12, 178-85		16
2206	A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1519-30; quiz 1665	11.9	380
2205	Improving depression outcome: new concepts, strategies and technologies. 2006 , 20, 3-4		2
2204	Depression and cardiovascular disease: healing the broken-hearted. 2006 , 295, 2874-81		178
2203	A Review of the STAR*D Trial. 2006 , 19, 353-360		
2202	Challenges in the treatment of anxiety disorders: beyond guidelines. 2006 , 10 Suppl 3, 18-24		1
2201	Twenty-five years of psychological treatment research on unipolar depression in adult outpatients: Introduction to the special section. 2006 , 16, 519-525		9
2200	Medication augmentation after the failure of SSRIs for depression. 2006 , 354, 1243-52		748
2199	Emerging treatments for depression. 2006 , 7, 2323-39		21

2198	Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1905-17	11.9	3098
2197	Combination pharmacotherapy in unipolar depression. 2006 , 6, 1049-60		9
2196	A perspective on the emergence of meditation techniques for medical disorders. 2006 , 12, 709-13		3
2195	Treatment of recurrent depression. 2006 , 6, 1735-40		14
2194	Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. 2007 , 32, 2479-89		106
2193	Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 739-52	11.9	246
2192	Paroxetine: current status in psychiatry. 2007 , 7, 107-20		36
2191	Neurogenetics of Psychiatric Disorders. 2007 ,		
2190	Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. <i>American Journal of Psychiatry</i> , 2007 , 164, 1530-8	11.9	171
2189	Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. 2007 , 32, 257-62		73
2188	Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. 2007 , 64, 689-97		106
2187	Cytochrome P450 genotyping and antidepressants. 2007 , 334, 759		11
2186	Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. <i>American Journal of Psychiatry</i> , 2007 , 164, 1181-8	11.9	169
2185	Keeping our depressed patients in the right treatment long enough for them to get better: some hopeful findings. <i>American Journal of Psychiatry</i> , 2007 , 164, 1136-9	11.9	1
2184	Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 1189-97	11.9	106
2183	Effect of age at onset on the course of major depressive disorder. <i>American Journal of Psychiatry</i> , 2007 , 164, 1539-46	11.9	295
2182	Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders. 2007 , 7, 63-74		33
2181	Making sense of evidence. 2007 , 19, 583-91		2

2180	Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. 2007 , 64, 783-92	182
2179	Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. 2007 , 5, 126-34	79
2178	Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. 2007 , 297, 367-79	474
2177	A preclinical and clinical rationale for quetiapine in mood syndromes. 2007 , 8, 1211-9	46
2176	Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. 2007 , 64, 679-88	78
2175	Outcome in a specialist referral clinic for mood disorders: a qualitative and quantitative review. 2007 , 15, 125-9	4
2174	Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. 2007 , 9, 826-35	46
2173	Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. 2007 , 52, 553-62	44
2172	Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. 2007 , 12, 703-11	18
2171	Exercise and pharmacotherapy in the treatment of major depressive disorder. 2007 , 69, 587-96	536
2170	CRH-sub-1 receptor antagonists for the treatment of depression and anxiety. 2007 , 15, 519-28	46
2169	Maximizing treatment outcomes in the depressed patient. 2007 , 68, 373-5	2
2168	Citalopram versus other anti-depressive agents for depression. 2007 ,	10
2167	Use of Decision Support Tools for Treatment Algorithms. 2007 , 12, 9-16	2
2166	Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. 2007 , 27, 614-9	37
2165	Psychopharm Review: CME QUIZ. 2007 , 42, 50	1
2164	An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. 2007 , 27, 219-21	5
2163	N-acetyl cysteine in the treatment of grooming disorders. 2007 , 27, 227-9	80

2162	Time-dependent clearance decrements of fluvoxamine in depressed inpatients: a clinical evaluation. 2007 , 27, 231-3	1
2161	A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. 2007 , 22, 338-47	73
2160	An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. 2007 , 27, 207-10	36
2159	Changes in hippocampal volume in patients with post-traumatic stress disorder after sertraline treatment. 2007 , 27, 233-5	29
2158	Smoking cessation in schizophrenia. 2007 , 27, 239-40; author reply 240	1
2157	Aripiprazole and neuroleptic malignant syndrome. 2007 , 27, 212-4	8
2156	Ethnicity/race and outcome in the treatment of depression: results from STAR*D. 2007 , 45, 1043-51	43
2155	The Use and Clinical Significance of Transcranial Magnetic Stimulation in the Treatment of Major Depression. 2007 , 42, 43-49	4
2154	Atypical antipsychotic drug-induced acute laryngeal dystonia: 2 case reports. 2007 , 27, 206-7	17
2153	Adjuvant levetiracetam in adolescent mania. 2007 , 27, 215-6	7
2152	Pancytopenia associated with the introduction of oxcarbazepine. 2007 , 27, 217-8	10
2151	Manic episode with psychotic symptoms associated with high dose of disulfiram: a case report. 2007 , 27, 224-5	12
2150	Reply to Comments by Dr Babbar. 2007 , 27, 240	
2149	Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression. 2007 , 27, 216-7	8
2148	Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. 2007 , 27, 237-8	14
2147	Exposure to nitrous oxide may be associated with high homocysteine plasma levels and a risk for clinical depression. 2007 , 27, 238-9	2
2146	STAR*D: what have we learned?. <i>American Journal of Psychiatry</i> , 2007 , 164, 201-4	11.9 250
2145	Acute nocturnal akathisia induced by clozapine. 2007 , 27, 205	4

2144	A 6-month longitudinal study of early-onset tardive dyskinesia: association with olanzapine treatment and mild cognitive impairment in an elderly woman. 2007 , 27, 210-2	4
2143	Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy. 2007 , 27, 221-4	13
2142	Escitalopram for compulsive buying disorder: a double-blind discontinuation study. 2007 , 27, 225-7	87
2141	The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. 2007 , 27, 241-5	47
2140	Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. 2007 , 22, 179-82	46
2139	Escitalopram-associated serotonin toxicity. 2007 , 27, 229-30	5
2138	Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease. 2007 , 27, 235-7	1
2137	Olanzapine-associated bilateral eyelid edema. 2007 , 27, 214-5	10
2136	Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. 2007 , 88 Suppl 2, S61-71	74
2135	Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale. 2007 , 28, 192-212	17
2134	Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features. 2007 , 48, 497-503	5
2133	An association between negatively biased response to neutral stimuli and antidepressant nonadherence. 2007 , 62, 535-44	6
2132	Treatment of postnatal depression in low-income mothers in primary-care clinics in Santiago, Chile: a randomised controlled trial. 2007 , 370, 1629-37	124
2131	P.2.c.014 Mecamylamine as an augmentation treatment for depressed patients who were non-responders to citalopram. 2007 , 17, S348-S349	2
2130	P.2.c.015 Better sexual acceptability of agomelatine compared to paroxetine in healthy male volunteers using the PRSexDQ Scale. 2007 , 17, S349	6
2129	P.2.c.016 Comparative efficacy of escitalopram and duloxetine in the acute treatment of major depressive disorder. 2007 , 17, S349-S350	
2128	The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. 2007 , 21, 461-71	253
2127	Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. 2007 , 23, 1303-18	47

2126	Combined treatments for major depression. 2007 , 16, 1379-89	1
2125	Costs and benefits of direct-to-consumer advertising: the case of depression. 2007 , 25, 511-21	17
2124	Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care. 2007 , 34, 505-19, vi	40
2123	Escitalopram prevents relapse in older patients with major depressive disorder. 2007 , 15, 581-93	59
2122	Mental health of US Gulf War veterans 10 years after the war. 2007 , 190, 385-93	63
2121	The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. 2007 , 30, 105-24	51
2120	Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. 2007 , 61, 734-42	133
2119	Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. 2007 , 61, 822-5	160
2118	Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. 2007 , 62, 1208-16	1074
2117	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. 2007 , 62, 1371-9	33
2116	Depressed neuroplasticity in major depressive disorder?. 2007 , 62, 371-2	11
2115	The pharmacogenetics of major depression: past, present, and future. 2007 , 62, 1205-7	21
2114	Triple uptake inhibitors: therapeutic potential in depression and beyond. 2007 , 16, 1365-77	90
2113	Long-term treatment of depression with antidepressants: a systematic narrative review. 2007 , 52, 545-52	19
2112	CNS volume 12 supplement 13 Cover and Back matter. 2007 , 12, b1-b3	1
2111	Bibliography. Current world literature. Addictive disorders. 2007 , 20, 286-304	
2110	Risk of Recurrence of Depression During Long-Term Antidepressant Treatment. 2007 , 12, 1-7	201
2109	Magnetic Seizure Therapy for the Treatment of Depression. 2007 , 155-171	4

2108	Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. 2007 , 12, 10-2	31
2107	Classifying eating disorders in DSM-V: new nosological perspectives. 2007 , 40 Suppl, S8-9	4
2106	Supplementary dimensional assessment in anxiety disorders. 2007 , 16 Suppl 1, S52-64	70
2105	Variants in PDE11A and PDE1A are not associated with citalopram response. 2007 , 12, 1061-3	10
2104	The art of prescribing. Monotherapy antidepressant: a thing of the past? Implications for the treatment of major depressive disorder. 2007 , 43, 142-5	4
2103	Pediatric bipolar disorder: evidence-based psychopharmacological treatments. 2007 , 20, 40-58	8
2102	Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. 2007 , 4, 917-29	89
2101	Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. 2007 , 41, 338-43	53
2100	Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. 2007 , 42, 962-71	26
2099	[Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making]. 2007 , 78, 1014-27	9
2098	[Pharmacological therapy for therapy-resistant depression. New developments]. 2007 , 78 Suppl 3, 551-63; quiz 564	1
2097	The STAR*D Project results: a comprehensive review of findings. 2007 , 9, 449-59	443
2096	The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. 2007 , 9, 467-74	175
2095	Rapid onset of true antidepressant action. 2007 , 9, 475-9	11
2094	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. 2008 , 37, 906-916	68
2093	Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. 2008 , 200, 557-72	77
2092	To Screen or Not to Screen: Conceptual Issues in Screening for Psychiatric Disorders in Psychiatric Patients with a Focus on the Performance of the Psychiatric Diagnostic Screening Questionnaire. 2008 , 6, 53-63	7
2091	Using interpersonal therapy (IPT) with older adults today and tomorrow: a review of the literature and new developments. 2008 , 10, 16-22	21

2090	Use of atypical antipsychotics for treatment-resistant major depressive disorder. 2008 , 10, 481-6	17
2089	Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. 2008 , 23, 551-60	74
2088	Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial. 2008 , 25, E173-81	7
2087	Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. 2008 , 23, 707-13	12
2086	The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. 2008 , 23, 55-9	18
2085	Treatment-resistant depression: critique of current approaches. 2008 , 42, 751-62	42
2084	Bipolar disorder: candidate drug targets. 2008 , 75, 226-47	42
2083	Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. 2008 , 117, 253-9	95
2082	When illness does not get better: do we need a palliative psychiatry?. 2008 , 20, 165-166	8
2081	The molecular neurobiology of depression. 2008 , 455, 894-902	1915
2080	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. 2008 , 7, 426-37	633
2079	Redefining affective disorders: relevance for drug development. 2008 , 14, 2-9	9
2078	Effect of different challenge doses after repeated citalopram treatment on extracellular serotonin level in the medial prefrontal cortex: in vivo microdialysis study. 2008 , 62, 568-74	3
2077	The modern pharmacopoeia: a return to depressive realism?. 2008 , 10, 969-72	2
2076	Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. 2008 , 10, 957-68	98
2075	Effect of co-administration of the selective 5-HT _{1A} receptor antagonist WAY 100,635 and selective 5-HT _{1B/1D} receptor antagonist GR 127,935 on anxiolytic effect of citalopram in conditioned fear stress in the rat. 2008 , 586, 171-8	21
2074	Patient education and group counselling to improve the treatment of depression in primary care: a randomized controlled trial. 2008 , 105, 235-40	20
2073	Patterns of response to repetitive transcranial magnetic stimulation (rTMS) in major depression: replication study in drug-free patients. 2008 , 108, 59-70	49

2072	Novel drugs and therapeutic targets for severe mood disorders. 2008 , 33, 2080-92	171
2071	Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. 2008 , 63, 699-704	191
2070	The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. 2008 , 63, 1103-10	218
2069	Brain stimulation, revolutions, and the shifting time domain of depression. 2008 , 64, 447-8	3
2068	Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. 2008 , 16, 225-34	38
2067	Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. 2008 , 8, 1787-97	13
2066	Pharmacotherapy of mood disorders. 2008 , 4, 53-91	53
2065	Pharmacogenomics and Personalized Medicine. 2008 ,	2
2064	L-methylfolate in the Therapeutic Management of Major Depressive Disorder. 2008 , 21, 278-286	5
2063	Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. 2008 , 22, 343-96	341
2062	Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. 2008 , 57, 203-9	298
2061	Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. 2008 , 13 Suppl 1, S1-29	161
2060	The pharmacological treatment of depression in adults with epilepsy. 2008 , 9, 3159-68	32
2059	Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. 2008 , 23, 350-5	101
2058	Cognitive behaviour therapy for depressed Pakistani mothers. 2008 , 372, 2111; author reply 2111-2	
2057	Prediction of response to antidepressants: is quantitative EEG (QEEG) an alternative?. 2008 , 14, 263-5	10
2056	Depression in long-term care. 2008 , 9, 82-7	109
2055	Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. 2008 , 16, 58-64	32

2054	Does direct-to-consumer advertising of antidepressants lead to a net social benefit?. 2008 , 26, 557-66; discussion 567-8	6
2053	Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. 2008 , 12, 321-30	17
2052	Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. 2008 , 9, 102-14	77
2051	Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. 2008 , 40, 149-59	71
2050	Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. 2008 , 37, 714-24	47
2049	Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. 2008 , 196, 136-43	100
2048	Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. 2008 , 42, 346-9	17
2047	Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 2008 , 65, 870-80	125
2046	Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder?. 2008 , 4, 377-393	
2045	Development and outcomes of a psychiatric pharmacy clinic for indigent patients. 2008 , 65, 229-33	24
2044	Mindfulness-based cognitive therapy for treatment-resistant depression: a pilot study. 2008 , 77, 319-20	108
2043	Pharmacogenomics with antidepressants in the STAR*D study. 2008 , 9, 935-46	50
2042	Current evidence for aripiprazole as augmentation therapy in major depressive disorder. 2008 , 8, 1435-47	8
2041	Recent Findings in the Pathophysiology of Depression. 2008 , 6, 3-14	16
2040	A surveillance study of escitalopram treatment of depressed patients. 2008 , 9, 1-6	16
2039	Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2008 , 165, 342-51	11.9 594
2038	A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. 2008 , 38, 323-33	68
2037	Remission in depression--is it a realistic goal?. 2008 , 62, 421-2	1

2036	Depressed patients' acceptability of the use of self-administered scales to measure outcome in clinical practice. 2008 , 20, 125-9		29
2035	Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*D) study. 2008 , 33, 2810-9		89
2034	Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. 2008 , 20, 209-18		45
2033	Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. 2008 , 9, 1725-36		21
2032	Agomelatine treatment of major depressive disorder. 2008 , 42, 1822-31		58
2031	An open-label study of citalopram for major depression following traumatic brain injury. 2008 , 22, 860-4		55
2030	Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder. 2008 , 11, 111		4
2029	The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?. 2008 , 11, 97-9		4
2028	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. 2008 , 6, 128-142		9
2027	Empirically derived decision trees for the treatment of late-life depression. <i>American Journal of Psychiatry</i> , 2008 , 165, 855-62	11.9	58
2026	Anxious depression and response to treatment. <i>American Journal of Psychiatry</i> , 2008 , 165, 297-9	11.9	31
2025	Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , 2008 , 165, 1136-47	11.9	146
2024	Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. 2008 , 5, 253-61		22
2023	Developing the evidence for evidence-based practice. 2008 , 178, 1313-5		4
2022	The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. 2008 , 12, 1347-66		60
2021	Genetic variation in GRIK4 and the implications for antidepressant treatment. 2008 , 9, 133-5		3
2020	Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. 2008 , 8, 1299-306		13
2019	Desvenlafaxine: another "me too" drug?. 2008 , 42, 1439-46		16

2018	Desvenlafaxine succinate for the treatment of major depressive disorder. 2008 , 9, 2129-36	5
2017	Folate and unipolar depression. 2008 , 14, 277-85	44
2016	The serotonin transporter polymorphisms and major depression following traumatic brain injury. 2008 , 22, 471-9	26
2015	The mental health clinic: a new model. 2008 , 7, 177-81	8
2014	Diagnostic co-morbidity in 2300 psychiatric out-patients presenting for treatment evaluated with a semi-structured diagnostic interview. 2008 , 38, 199-210	49
2013	The opportunity for psychiatry in palliative care. 2008 , 53, 713-24	38
2012	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. 2008 , 6, 104-119	
2011	Strategies for the Prevention and Treatment of Suicidal Behavior. 2008 , 6, 15-21	3
2010	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. 2008 , 76, 459-67	44
2009	Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. 2008 , 13, 1066-86; quiz 1087-8	125
2008	Major depressive disorder: epidemiology, course of illness, and treatment. 2008 , 13, 4-7	3
2007	Pharmacogenetics of antidepressant response: an update. 2009 , 3, 257-74	30
2006	The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. 2008 , 18, 184-90	48
2005	Identifying inter-ethnic variations in psychotropic response in African Americans and other ethnic minorities. 111-117	3
2004	Pharmacokinetics of sertraline across pregnancy and postpartum. 2008 , 28, 646-53	46
2003	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. 2008 , 6, 69-79	
2002	Collaborative mental health and primary care for bipolar disorder. 2008 , 14 Suppl 2, 55-64	5
2001	Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry?. 2008 , 59, 1148-54	66

2000	A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. 2008 , 50, 428-36	45
1999	Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. 2008 , 14, 34-44	48
1998	An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. 2008 , 14, 271-80	34
1997	Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. 2008 , 23, 113-9	44
1996	Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. 2008 , 18, 248-51	14
1995	Psychopharmacology of mood disorders. 481-497	
1994	The evolution of deep brain stimulation for neuropsychiatric disorders. 2008 , 13, 4638-48	33
1993	Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. 2008 , 53, 361-70	117
1992	Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders. 2008 , 1, 1-6	4
1991	Major depression is sometimes described as the common cold of psychiatry. 2008 , 22, 3	62
1990	Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. 2009 , 14, 487-98	8
1989	Introduction and Clinical Presentations. 2009 , 14, 4-6	4
1988	Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. 2009 , 5, 369-83	13
1987	Predictive value of self-reported and observer-rated defense style in depression treatment. 2009 , 63, 25-39	15
1986	Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. 2010 , 4, 67-82	8
1985	Desvenlafaxine in the treatment of major depressive disorder. 2009 , 5, 127-36	12
1984	Uncertainty and practical reasoning in clinical psychiatry and neurology. 2009 , 14, 284-5	6
1983	The quest for a meaningful evidence base in psychiatry. 2009 , 8, 33-4	4

1982	Effectiveness as an outcome measure for treatment trials in psychiatry. 2009 , 8, 23-7	14
1981	Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. 2009 , 10, 3061-75	26
1980	Conceptual Models of Depression in Primary Care Patients: A Comparative Study. 2009 , 40, 1041-1059	19
1979	Commentary on STAR*D: a summary and UK perspective. 2009 , 23, 615-7; discussion 622-4	
1978	Commentary on STAR*D: a summary and UK perspective. 2009 , 23, 613-4; discussion 622-4	2
1977	Evaluation of an outpatient intervention for women with severe depression and a history of childhood trauma. 2009 , 60, 936-42	46
1976	Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence. 2009 , 40, 78-83	19
1975	What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 2009 , 60, 1439-45	368
1974	Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. 2009 , 9, 975-84	50
1973	Management of stress in inflammatory bowel disease: a therapeutic option?. 2009 , 3, 661-79	37
1972	Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. 2009 , 10, 2145-59	15
1971	On Chemical Imbalances, Antidepressants, and the Diagnosis of Depression. 2009 , 11, 199-214	4
1970	Brief intervention for anxiety in primary care patients. 2009 , 22, 175-86	31
1969	Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. 2009 , 59, 227-33	27
1968	Moderation of antidepressant response by the serotonin transporter gene. 2009 , 195, 30-8	124
1967	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. 2009 , 43, 956-967	8
1966	A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. 2009 , 66, 966-975	259
1965	Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. 2009 , 66, 1304-12	142

1964	STAR*D: a summary and UK perspective. 2009 , 23, 605-12		8
1963	Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version. 2009 , 78, 116-24		12
1962	Identifying risk for attrition during treatment for depression. 2009 , 78, 372-9		20
1961	Depression in epilepsy: mechanisms and therapeutic approach. 2009 , 2, 337-44		54
1960	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. 2009 , 2, 66-87		1
1959	Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. 2009 , 29, 327-33		61
1958	Antidepressant switching among adherent patients treated for depression. 2009 , 60, 617-23		18
1957	Emerging drugs for major depressive disorder. 2009 , 14, 439-53		24
1956	Pharmacological developments in the treatment of depression. 2009 , 23, 40-7; quiz 50		1
1955	Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. <i>American Journal of Psychiatry</i> , 2009 , 166, 599-607	11.9	171
1954	The conceptual development of DSM-V. <i>American Journal of Psychiatry</i> , 2009 , 166, 645-50	11.9	258
1953	Treatment-resistant depression and mortality after acute coronary syndrome. <i>American Journal of Psychiatry</i> , 2009 , 166, 410-7	11.9	116
1952	A call for simple and rational palliative medicine psychotropic prescribing guidelines: Response to Barnhorst et al. (<i>Palliative & Supportive Care</i> , Volume 6, Number 1, 2008). 2009 , 7, 3-6		
1951	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. 2009 , 60, 1446-1457		58
1950	Depression in neurological practice: diagnosis, treatment, implications. 2009 , 29, 220-33		8
1949	Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. 2009 , 34, 1819-28		78
1948	Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results. 2009 , 9, 39-41		2
1947	When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. 2009 , 34, 2227-36		70

1946	Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. 2009 , 34, 2275-84	75
1945	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. 2009 , 12, 459-73	58
1944	Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. 2009 , 34, 999-1010	62
1943	A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. 2009 , 35, 384-9	14
1942	STAR*D: has it taught us anything about the management of depression?. 2009 , 17, 360-4	5
1941	Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. 2009 , 14, 197-206	207
1940	Ketamine and the next generation of antidepressants with a rapid onset of action. 2009 , 123, 143-50	209
1939	Pharmacogenomics of antidepressant drugs. 2009 , 124, 57-73	94
1938	Midline and right frontal brain function as a physiologic biomarker of remission in major depression. 2009 , 174, 152-7	45
1937	Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. 2009 , 43, 215-29	142
1936	A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. 2009 , 43, 205-14	80
1935	Sex differences in response to citalopram: a STAR*D report. 2009 , 43, 503-11	123
1934	Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. 2009 , 31 Pt 1, 1405-23	53
1933	Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?. 2009 , 115, 234-40	17
1932	Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. 2009 , 114, 243-53	57
1931	Clinically significant change in psychotherapy for depressive disorders. 2009 , 115, 220-4	8
1930	Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. 2009 , 115, 439-49	125
1929	What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. 2009 , 116, 4-11	194

1928	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. 2009 , 117, 63-73	73
1927	Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. 2009 , 118, 94-100	40
1926	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. 2009 , 117 Suppl 1, S26-43	298
1925	SLC6A4 variation and citalopram response. 2009 , 150B, 341-51	108
1924	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. 2009 , 24, 269-75	39
1923	Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. 2009 , 26, 83-97	76
1922	Income and attrition in the treatment of depression: a STAR*D report. 2009 , 26, 622-33	39
1921	Diurnal mood variation in outpatients with major depressive disorder. 2009 , 26, 851-63	18
1920	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. 2009 , 26, 612-21	25
1919	Childhood neglect and abuse as predictors of antidepressant response in adult depression. 2009 , 26, 711-7	38
1918	A dimensional versus a categorical approach to diagnosis: anxiety and depression in the HUNT 2 study. 2009 , 18, 128-37	52
1917	Release bias in accessing medical records in clinical trials: a STAR*D report. 2009 , 18, 147-58	1
1916	Is evidence sufficient for evidence-based medicine?. 2009 , 259 Suppl 2, S167-72	9
1915	Just How Effective are Antidepressant Medications? Results of a Major New Study. 2009 , 39, 93-100	2
1914	Translating evidence to practice: two stories from the field. 2009 , 16, 47-57	21
1913	Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats. 2009 , 32, 1281-92	37
1912	Socioeconomic status and anxiety as predictors of antidepressant treatment response and suicidal ideation in older adults. 2009 , 44, 272-7	54
1911	A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. 2009 , 9, 78	43

1910	A validation analysis of two self-reported HAM-D6 versions. 2009 , 119, 298-303	32
1909	Social phobia in late-life: is it worth a diagnosis?. 2010 , 122, 1-3	0
1908	Association between painful physical symptoms and clinical outcomes in East Asian patients with major depressive disorder: a 3-month prospective observational study. 2009 , 63, 1041-9	33
1907	CRH signaling. Molecular specificity for drug targeting in the CNS. 2009 , 1179, 106-19	49
1906	Emerging targets for antidepressant therapies. 2009 , 13, 291-302	55
1905	Selegiline transdermal system: a novel treatment option for major depressive disorder. 2009 , 10, 1665-73	12
1904	Depression. 2009 ,	
1903	Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. 2009 , 99, 248-60	109
1902	Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. 2009 , 219, 36-43	41
1901	Treatment resistant depression as a failure of brain homeostatic mechanisms: implications for deep brain stimulation. 2009 , 219, 44-52	80
1900	Telephone-based assessments to minimize missing data in longitudinal depression trials: a project IMPACTS study report. 2009 , 30, 13-9	12
1899	The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. 2009 , 30, 484-93	118
1898	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. 2009 , 169, 132-8	95
1897	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. 2009 , 169, 124-31	140
1896	Measuring and distilling the impact of pain. 2009 , 142, 7-8	4
1895	Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. 2009 , 33, 113-7	20
1894	Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. 2009 , 33, 616-24	53
1893	Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. 2009 , 33, 722-6	145

1892	Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression. 2009 , 463, 26-30	17
1891	Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. 2009 , 466, 149-53	12
1890	Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. 2009 , 65, 289-95	219
1889	Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression. 2009 , 65, 392-400	162
1888	Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. 2009 , 65, 785-91	73
1887	The Maudsley Prescribing Guidelines. 2009 ,	110
1886	Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. 2009 , 29, 173-84	10
1885	Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. 2009 , 10, 180-95	16
1884	The antidepressive effects of exercise: a meta-analysis of randomized trials. 2009 , 39, 491-511	371
1883	Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. 2009 , 18, 1753-64	49
1882	Neurocognitive mechanisms in depression: implications for treatment. 2009 , 32, 57-74	301
1881	Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. 2009 , 34, 522-34	219
1880	Phosphodiesterase genes and antidepressant treatment response: a review. 2009 , 41, 177-85	25
1879	Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. 2009 , 27, 507-17	22
1878	STAR*D: revising conventional wisdom. 2009 , 23, 627-47	172
1877	Agomelatine: efficacy at each phase of antidepressant treatment. 2009 , 23 Suppl 2, 41-7	17
1876	Antidepressant treatment patterns and costs among US employees. 2009 , 12, 36-45	2
1875	Disability from depression: the public health challenge to primary care. 2009 , 63, 17-21	10

1874	Depression and Diabetes: Factors Associated With Major Depression at Five-Year Follow-Up. 2009 , 50, 570-579	91
1873	Objective: remission of depression in primary care The Oreon Study. 2009 , 19, 169-76	21
1872	Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. 2009 , 19, 457-65	101
1871	Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. 2009 , 19, 520-32	101
1870	Frontal EEG predictors of treatment outcome in major depressive disorder. 2009 , 19, 772-7	128
1869	The primacy of mania: a reconsideration of mood disorders. 2009 , 24, 125-34	41
1868	European Brain Policy Forum 2009: depression and the European society. 2009 , 24, 550-1	7
1867	Depression and costs of health care. 2009 , 50, 392-401	57
1866	The impact of nonclinical factors on care use for patients with depression: a STAR*D report. 2009 , 15, 320-32	9
1865	Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. 2009 , 48, 997-1004	56
1864	Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. 2009 , 6, 217-224	21
1863	Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. 2009 , 15, 113-24	22
1862	Clinical inertia in depression treatment. 2009 , 47, 959-67	33
1861	Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. 2009 , 24, 61-86	12
1860	Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. 2009 , 24, 133-8	72
1859	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. 2009 , 24, 250-6	57
1858	Results of the STAR*D study: implications for clinicians and drug developers. 2009 , 15, 45-9	22
1857	Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. 2009 , 19, 1-10	73

1856	Measuring outcomes makes good sense. 2009 , 60, 112	4
1855	Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. 2009 , 24, 19-25	29
1854	Transdermal estradiol for postpartum depression: a promising treatment option. 2009 , 52, 516-29	73
1853	Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?. 2009 , 15, 337-45	8
1852	Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 2009 , 19, 666-74	80
1851	Low-dose transdermal testosterone augmentation therapy improves depression severity in women. 2009 , 14, 688-94	44
1850	The role of L-methylfolate in depressive disorders. 2009 , 14, 2-7	36
1849	Long-term management of depression: tips for adjusting the treatment plan as the patient's needs change. 2009 , 70 Suppl 6, 32-7	5
1848	Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. 2009 , 77, 775-87	228
1847	The Bypassing the Blues treatment protocol: stepped collaborative care for treating post-CABG depression. 2009 , 71, 217-30	52
1846	Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. 2009 , 15, 1595-611	96
1845	Treatment options for the patient who does not respond well to initial antidepressant therapy. 2009 , 15, 202-10	9
1844	Culturally sensitive collaborative treatment for depressed chinese americans in primary care. 2010 , 100, 2397-402	63
1843	Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. 2010 , 25, 199-203	18
1842	The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. 2010 , 55, 126-35	199
1841	Do atypical features affect outcome in depressed outpatients treated with citalopram?. 2010 , 13, 15-30	41
1840	S-adenosyl methionine (SAME) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. <i>American Journal of Psychiatry</i> , 2010 , 167, 942-8	11.9 229
1839	Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial. 2010 , 25, 51-9	4

1838	Transcranial Magnetic Stimulation for the Treatment of Major Depression. 2010 , 45, 57-66	2
1837	Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. 2010 , 30, 357-64	43
1836	Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. 2010 , 25, 17-21	13
1835	Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. 2010 , 30, 259-66	17
1834	A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support. 2010 , 25, 288-96	26
1833	Efficacy of exercise in reducing depressive symptoms across 5-HTTLPR genotypes. 2010 , 42, 2141-7	16
1832	Natural course, placebo effect, and sham electroconvulsive therapy. 2010 , 26, 76	1
1831	A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. 2010 , 30, 300-5	11
1830	Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. 2010 , 71, e1-e21	81
1829	Novel Therapeutic Strategies for Bipolar Disorder. 2010 , 395-411	
1828	Unmet Needs in the Management of Major Depressive Disorder. 2010 , 15, 4-7	3
1827	[Diverse and frequent--depressive disorders in general practice]. 2010 , 152, 60-3; quiz 64	
1826	Clinical utility in the revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM).. 2010 , 41, 465-473	53
1825	Imaging genetics: implications for research on variable antidepressant drug response. 2010 , 3, 471-89	11
1824	Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. 2010 , 212, 1-12	128
1823	A critical review of human endotoxin administration as an experimental paradigm of depression. 2010 , 34, 130-43	124
1822	Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. 2010 , 260, 145-50	27
1821	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. 2010 , 260, 25-39	31

1820	Biomarkers to predict antidepressant response. 2010 , 12, 553-62	111
1819	Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. 2010 , 44, 90-8	50
1818	The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. 2010 , 126, 173-85	56
1817	Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. 2010 , 11, 204	26
1816	The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword. 2010 , 32 Suppl 1, S1-2	1
1815	The impact of diabetes on depression treatment outcomes. 2010 , 32, 33-41	20
1814	Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. 2010 , 120, 133-40	30
1813	Depression and comorbid panic in primary care patients. 2010 , 123, 283-90	6
1812	Patients' beliefs about the cause of their depression. 2010 , 124, 54-9	30
1811	Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. 2010 , 127, 337-42	27
1810	Association between painful physical symptoms and clinical outcomes in Taiwanese patients with major depressive disorder: A three-month observational study. 2010 , 2, 136-145	1
1809	Major depression: the importance of clinical characteristics and treatment response to prognosis. 2010 , 27, 19-26	67
1808	Ethnic differences in antidepressant response: a prospective multi-site clinical trial. 2010 , 27, 56-62	25
1807	Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. 2010 , 27, 12-8	40
1806	An adjunctive Management of Depression Program for difficult-to-treat depressed patients and their families. 2010 , 27, 27-34	8
1805	Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. 2010 , 20, 5847-52	20
1804	Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. 2010 , 9, 10	10
1803	The adverse effects of comorbid pain on depression outcomes in primary care patients: results from the ARTIST trial. 2010 , 11, 732-41	42

1802	No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. 2010 , 121, 174-9	54
1801	Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS-C16 and QIDS-SR16) in the elderly. 2010 , 122, 226-34	26
1800	Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. 2010 , 64, 1310-7	34
1799	Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior. 2010 , 15, 1164-75	88
1798	Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. 2010 , 64, 367-71	10
1797	The king is dead, long live the king! The restoration of BALANCE. 2010 , 12, 681-4	7
1796	Current nosology of treatment resistant depression: a controversy resistant to revision. 2010 , 6, 20-4	27
1795	Unmet Needs in the Management of Major Depressive Disorder. 2010 , 15, 8-10	
1794	Confounding placebo response in clinical trials: Analysing the little we know and current strategies to address the crisis. 2010 , 16, 3	
1793	Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy. 2010 , 4, 35	59
1792	The Impact of Residual Symptoms in Major Depression. 2010 , 3, 2426-2440	29
1791	Neurobiological alterations induced by exercise and their impact on depressive disorders [corrected]. 2010 , 6, 115-25	50
1790	Preface. 2010 , VI-VIII	
1789	A eficácia do milnaciprano em pacientes ambulatoriais com transtorno depressivo maior não respondedores ao tratamento com ISRSs: um estudo aberto de 12 semanas. 2010 , 37, 241-245	1
1788	Practice-based learning and systems-based practice: detection and treatment monitoring of generalized anxiety and depression in primary care. 2010 , 2, 474-7	5
1787	Eficacia y costos asociados a un tratamiento ambulatorio en mujeres con depresión severa y trauma temprano. 2010 , 138,	1
1786	Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. 2010 , 75, 448-55	176
1785	Improving depression care in a psychiatry resident psychopharmacology clinic: measurement, monitoring, feedback and education. 2010 , 19, 234-8	8

1784	Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. 2010 , 5, e10404		141
1783	Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study. 2010 , 24, 1201-7		7
1782	Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. 2010 , 79, 331-8		46
1781	A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia: Erratum. 2010 , 30, 364		
1780	Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. 2010 , 40, 239-51		66
1779	Antidepressant pharmacotherapy in adults with type 2 diabetes: rates and predictors of initial response. 2010 , 33, 485-9		24
1778	Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. 2010 , 67, 507-16		644
1777	Personalized medicine for depression: can we match patients with treatments?. <i>American Journal of Psychiatry</i> , 2010 , 167, 1445-55	11.9	228
1776	Gender differences in antidepressant drug response. 2010 , 22, 485-500		107
1775	Using pre-treatment EEG data to predict response to SSRI treatment for MDD. 2010 , 2010, 6103-6		12
1774	Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. <i>American Journal of Psychiatry</i> , 2010 , 167, 281-8	11.9	222
1773	Revoking serotonin's auto license. 2010 , 3, 137-137		1
1772	Therapy-resistant depression. 2010 , 10, 77-86		34
1771	Glutamatergic modulators: the future of treating mood disorders?. 2010 , 18, 293-303		168
1770	Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. 2010 , 10, 651-70		15
1769	The importance of early symptom relief in antidepressant treatment: focus on agomelatine. 2010 , 24, 27-30		14
1768	The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. 2010 , 24, 21-6		21
1767	Arzneiverordnungs-Report 2010. 2010 ,		28

1766	Gender differences among patients with a single depressive episode. 2010 , 43, 159-69		10
1765	Efficacy and effectiveness of antidepressants: current status of research. 2010 , 79, 267-79		225
1764	A hypericum extract in the treatment of depressive symptoms in outpatients: an open study. 2010 , 17, 7-14		5
1763	A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. 2010 , 43, 245-51		7
1762	Combining antidepressant medications: a good idea?. <i>American Journal of Psychiatry</i> , 2010 , 167, 241-3	11.9	22
1761	Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. <i>American Journal of Psychiatry</i> , 2010 , 167, 565-73	11.9	52
1760	Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. <i>American Journal of Psychiatry</i> , 2010 , 167, 574-9	11.9	39
1759	Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. 2010 , 67, 369-79		96
1758	Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. 2010 , 6, 1565-74		12
1757	Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. 2010 , 122, 125-38		6
1756	Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. 2010 , 43, 33-5		53
1755	Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany. 2010 , 43, 210-5		9
1754	Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. 2010 , 122, 39-48		128
1753	Therapeutic armamentarium for treating depression. 2010 , 122, 66-93		11
1752	Ejercicio y depresi3n. 2010 , 39, 732-748		0
1751	Culturally adapted pharmacotherapy and the integrative formulation. 2010 , 19, 791-814		11
1750	Tryptophan hydroxylase as novel target for the treatment of depressive disorders. 2010 , 85, 95-109		55
1749	Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. 2010 , 40, 41-50		283

1748	Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. 2010 , 35, 1415-22	175
1747	Basic Study Design. 2010 , 67-96	1
1746	Effects of estradiol on learned helplessness and associated remodeling of hippocampal spine synapses in female rats. 2010 , 67, 168-74	57
1745	A genomewide association study of citalopram response in major depressive disorder. 2010 , 67, 133-8	251
1744	Pioneering first steps and cautious conclusions. 2010 , 67, 99-100	5
1743	Learning as a model for neural plasticity in major depression. 2010 , 68, 544-52	89
1742	Open trial of Vinyasa yoga for persistently depressed individuals: evidence of feasibility and acceptability. 2010 , 34, 247-64	59
1741	Therapeutic options for treatment-resistant depression. 2010 , 24, 131-61	141
1740	¿Predice la mejoría precoz inducida por los antidepresivos la respuesta/remisión? Análisis de los datos de un estudio naturalista en una muestra a gran escala de pacientes hospitalizados con depresión mayor. 2010 , 17, 45-53	
1739	mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. 2010 , 329, 959-64	1868
1738	Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. 2010 , 13, 903-8	88
1737	Ambulatory emotional reactivity to negative daily life events predicts remission from major depressive disorder. 2010 , 48, 754-60	50
1736	Altered function of the serotonin 1A autoreceptor and the antidepressant response. 2010 , 65, 1-2	41
1735	Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. 2010 , 175, 67-73	22
1734	Correlation between patient and clinician assessments of depression severity in the PREVENT study. 2010 , 177, 177-83	33
1733	Geriatric Pharmacotherapy Updates. 2010 , 8, 175-182	
1732	Glutamate receptor ion channels: structure, regulation, and function. 2010 , 62, 405-96	2406
1731	RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). 2010 , 16, 322-5	94

1730	Linking molecules to mood: new insight into the biology of depression. <i>American Journal of Psychiatry</i> , 2010 , 167, 1305-20	11.9	471
1729	[Therapeutic strategy of depressive episodes. Prevention of relapse risk]. 2010 , 36 Suppl 5, S145-9		0
1728	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. 2010 , 20, 346-55		61
1727	The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. 2010 , 20, 459-66		67
1726	Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). 2010 , 35, 301-16		240
1725	Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives. 2010 , 254-267		2
1724	Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. 2010 , 26, 139-50		8
1723	Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. 2010 , 35, 727-40		153
1722	Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. 2010 ,		33
1721	Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. 2010 , 27, 625-40		22
1720	Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. 2010 , 24, 479-99		98
1719	Brain stimulation in psychiatry and its effects on cognition. 2010 , 6, 267-75		67
1718	Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. 2010 , 11, 709-22		48
1717	Pharmacogenetic considerations in the treatment of psychiatric disorders. 2010 , 11, 423-39		22
1716	Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study. 2010 , 14, 303-8		3
1715	Defining and measuring functional recovery from depression. 2010 , 24, 267-84		128
1714	Central functions of neuropeptide Y in mood and anxiety disorders. 2011 , 15, 1317-31		110
1713	Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. 2011 , 25, 109-27		62

1712	Corticotropin releasing factor receptor antagonists for major depressive disorder. 2011 , 20, 519-35	46
1711	Feasibility and impact of telemonitor-based depression care management for geriatric homecare patients. 2011 , 17, 620-6	25
1710	Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. 2011 , 27, 1815-26	3
1709	Management of nonpsychiatric medical conditions presenting with psychiatric manifestations. 2011 , 58, 219-41, xii	3
1708	Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. 2011 , 69, 360-5	28
1707	Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. 2011 , 69, 754-61	763
1706	Ventajas y desventajas del tratamiento de combinaci3n con antipsic3ticos. Reuni3n ECNP Consensus, marzo de 2008, Niza. 2011 , 18, 55-67	2
1705	[Glutamatergic antidepressants? The intriguing antidepressant properties of ketamine]. 2011 , 4, 183-6	4
1704	Glutamatergic antidepressants? The intriguing antidepressant properties of ketamine. 2011 , 4, 183-186	
1703	Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. 2011 , 31, 385-405	8
1702	Molecular and Functional Models in Neuropsychiatry. 2011 ,	0
1701	Diagnosis and treatment of major depressive disorder. 2011 , 29, 177-93, ix	26
1700	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. 2011 ,	5
1699	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. 2011 , 54, 3206-21	385
1698	Mirtazapine versus other antidepressive agents for depression. 2011 , CD006528	80
1697	Review of the use of mirtazapine in the treatment of depression. 2011 , 12, 1623-32	21
1696	Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 2011 , 9, 483-94	9
1695	Targeting remission by 8 weeks: when should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor?. 2011 , 52, 9-16	1

1694	Clinical differences between first and recurrent episodes in depressive patients. 2011 , 52, 26-32	13
1693	[Switch antidepressants: when? How? Why?]. 2011 , 37 Suppl 1, S50-7	1
1692	Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. 2011 , 1810, 1230-5	16
1691	Animal models of depression: molecular perspectives. 2011 , 7, 121-47	300
1690	Sertoli cell therapy: a novel possible treatment strategy for treatment-resistant major depressive disorder. 2011 , 77, 35-42	7
1689	Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression. 2011 , 77, 508-28	41
1688	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. 2011 , 59, 896-905	54
1687	Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. 2011 , 499, 74-9	40
1686	Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. 2011 , 501, 20-4	26
1685	Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders: the CRESCEND study. 2011 , 71, 311-8	8
1684	Stuck in a rut: rethinking depression and its treatment. 2011 , 34, 1-9	252
1683	Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. 2011 , 35, 395-409	192
1682	Genome-wide association studies of antidepressant outcome: a brief review. 2011 , 35, 1553-7	38
1681	LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. 2011 , 35, 1831-5	41
1680	Modeling treatment-resistant depression. 2011 , 61, 408-13	63
1679	Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. 2011 , 96, 553-63	222
1678	Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning. 2011 , 186, 133-7	40
1677	One-year severity of depressive symptoms: results from the NESDA study. 2011 , 190, 226-31	9

1676	Novelty-Suppressed Feeding in the Mouse. 2011 , 107-121	38
1675	C.11.02 Therapeutic strategies. 2011 , 21, S634-S635	
1674	Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. 2011 , 132 Suppl 1, S21-8	13
1673	Agomelatine: a narrative review. 2011 , 21 Suppl 4, S703-9	55
1672	Biological Alterations in Depression. 2011 ,	2
1671	An audit of non-urgent general adult referrals to Stikland State Psychiatric Facility. 2011 , 17, 4	
1670	Preoperative anesthetic assessment. 7-15	
1669	References. 2011 , 209-234	
1668	Commentary [the mood in the field of antidepressant drug discovery]. 2011 , 10, 762-3	3
1667	Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. 2011 , 7, 303-12	31
1666	Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder. 2011 , 2, 7	44
1665	Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA study. 2011 , 56, 348-57	13
1664	Introduction: Evidence-Based Practice for Major Depressive Disorder. 2011 , 1-19	
1663	Introduction to the concept of symptomatic epilepsy. 113-118	5
1662	Psychiatric disorders. 593-606	2
1661	Using gene-environment interactions to target personalized treatment in mood disorder. 2011 , 8, 23-34	9
1660	Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. 2011 , 31, 180-6	123
1659	Association between citalopram serum levels and clinical improvement of patients with major depression. 2011 , 31, 281-6	22

1658	Relationship between a history of a suicide attempt and treatment outcomes in patients with depression. 2011 , 31, 449-56	27
1657	CYP2C19 variation and citalopram response. 2011 , 21, 1-9	98
1656	PharmGKB summary: citalopram pharmacokinetics pathway. 2011 , 21, 769-72	36
1655	The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. 2011 , 31, 31-8	13
1654	Role of metabolic dysfunction in treatment resistance of major depressive disorder. 2011 , 1, 441-455	8
1653	Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. 2011 , 31, 569-76	64
1652	Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. 2011 , 62, 929-35	33
1651	Clinical and pharmacologic perspectives on the treatment of major depressive disorder. 2011 , 16, 191-203	4
1650	Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial. 2011 , 16, 17-33	122
1649	Long-term impact of residual symptoms in treatment-resistant depression. 2011 , 56, 549-57	7
1648	Pharmacogenetics of antidepressants. 2011 , 2, 6	55
1647	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. 2011 , 198, 464-71	51
1646	Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. 2011 , 65, 510-7	6
1645	Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. 2011 , 89, 97-104	125
1644	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. 2011 , 45, 96-103	34
1643	A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. 2011 , 45, 748-55	20
1642	Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. 2011 , 45, 1301-6	63
1641	The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. 2011 , 36, 339-51	83

1640	Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse. 2011 , 97, 566-76	33
1639	Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: cerebral perfusion and clinical implications. 2011 , 192, 125-30	17
1638	Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. 2011 , 192, 188-94	25
1637	The implication of functional connectivity strength in predicting treatment response of major depressive disorder: a resting EEG study. 2011 , 194, 372-377	33
1636	Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. 2011 , 128 Suppl 1, S11-20	24
1635	International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. 2011 , 12, 4	126
1634	Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. 2011 , 132, 14-25	22
1633	Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. 2011 , 129, 183-90	39
1632	Evaluating the first 1000 patients referred to a specialist depression clinic: a case for tertiary referral facilities. 2011 , 131, 52-8	9
1631	Clinical effectiveness, construct and assessment. 2011 , 132 Suppl 1, S3-8	3
1630	Clinical predictors of response and remission in inpatients with depressive syndromes. 2011 , 133, 137-49	60
1629	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 2011 , 133, 467-76	42
1628	Stressful events, stress perception and treatment outcomes in patients with depressive disorders: the CRESCEND study. 2011 , 133, 528-36	12
1627	The public health impact of antidepressants: an instrumental variable analysis. 2011 , 134, 188-97	12
1626	Clinical differences between early and late remission in depressive patients. 2011 , 134, 235-41	13
1625	Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study. 2011 , 134, 257-65	33
1624	Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. 2011 , 33, 1246-57	10
1623	Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective. 2011 , 33, 1726-38	2

1622	Solving the antidepressant efficacy question: effect sizes in major depressive disorder. 2011 , 33, B49-61	43
1621	Identification of short-acting μ -opioid receptor antagonists with anxiolytic-like activity. 2011 , 661, 27-34	41
1620	Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review. 2011 , 4, 17-27	49
1619	Cell atrophy and loss in depression: reversal by antidepressant treatment. 2011 , 23, 730-7	139
1618	Therapeutic options in treatment-resistant depression. 2011 , 43, 512-30	58
1617	Clinical correlates of health-related quality of life among opioid-dependent patients. 2011 , 20, 1205-13	12
1616	Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. 2011 , 261, 147-56	28
1615	Combined antidepressant strategies are not more effective than vigorous escitalopram monotherapy: results of the CO-MED study. 2011 , 13, 434-6	3
1614	Measurement-based care for unipolar depression. 2011 , 13, 446-58	21
1613	A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression. 2011 , 11, 166	11
1612	Do general practitioners and psychiatrists agree about defining cure from depression? The DEsCRIBE survey. 2011 , 11, 169	11
1611	Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder. 2011 , 11, 19	10
1610	Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. 2011 , 12, 116	20
1609	Transcriptional dysregulation of 5-HT _{1A} autoreceptors in mental illness. 2011 , 4, 21	95
1608	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. 2011 , 28, 267-81	20
1607	Star-D: lessons learned and future implications. 2011 , 28, 521-4	25
1606	The National Network of Depression Centers: progress through partnership. 2011 , 28, 615-21	8
1605	Depression treatment and maternal functioning. 2011 , 28, 1020-6	28

1604	Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. 2011 , 26, 41-50		26
1603	5-HT receptors and reward-related behaviour: a review. 2011 , 35, 1419-49		110
1602	Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. <i>American Journal of Psychiatry</i> , 2011 , 168, 593-602	11.9	124
1601	Antidepressants and adolescent brain development. 2011 , 6, 783-808		11
1600	Depression, smoking, and heart disease: how can psychiatrists be effective?. <i>American Journal of Psychiatry</i> , 2011 , 168, 876-8	11.9	7
1599	Duloxetine in the acute and continuation treatment of major depressive disorder. 2011 , 11, 1525-39		
1598	Electroencephalography-derived biomarkers of antidepressant response. 2011 , 19, 144-54		92
1597	The use of ECT and MST in treating depression. 2011 , 23, 400-12		37
1596	Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?. 2011 , 17, 330-9		30
1595	Frontocingulate dysfunction in depression: toward biomarkers of treatment response. 2011 , 36, 183-206		636
1594	Translating glutamate: from pathophysiology to treatment. 2011 , 3, 102mr2		127
1593	Brain stimulation therapies for mood disorders: the continued necessity of electroconvulsive therapy. 2011 , 17, 214-6		0
1592	The future of psychiatric pharmacogenomics. 2011 , 12, 927-9		2
1591	Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. 2011 , 62, 1167-79		25
1590	STAR*D: A Tale and Trail of Bias. 2011 , 13, 6-28		19
1589	Reanalyzing a Randomized Controlled Trial of Combination Antidepressant Treatment With Mirtazapine: Confidence Intervals Suggest Substantial Uncertainty. 2011 , 13, 149-154		1
1588	No medication without representation? Generalizing from antidepressant clinical efficacy trials to clinical practice. 2011 , 41, 1349-51		
1587	Use of risperidone as augmentation treatment for major depressive disorder. 2011 , 45, 95-100		11

1586	Racial differences in symptoms, comorbidity, and treatment for major depressive disorder among black and white adults. 2011 , 103, 576-84	50
1585	Commentary: Psychiatric training for physicians: a call to modernize. 2011 , 86, 285-7	16
1584	The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases. 2011 , 17, 2843-51	16
1583	Implementation of Collaborative Depression Management at Community-Based Primary Care Clinics: An Evaluation. 2011 , 62, 1047-1053	69
1582	BDNF Val66Met genotype and 6-month remission rates in late-life depression. 2011 , 11, 146-54	42
1581	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. 2011 , 11, 138-45	65
1580	Gene expression biomarkers of response to citalopram treatment in major depressive disorder. 2011 , 1, e13	53
1579	Targeting treatment-resistant depression. 2011 , 24, 520-33	12
1578	How to read a research paper: Reading between and beyond the lines. 2011 , 53, 362-6	2
1577	Glucocorticoids as predictors of treatment response in depression. 2011 , 19, 125-43	24
1576	Relationship between depressive symptoms and hypogonadism in men with COPD. 2011 , 8, 346-53	8
1575	Repetitive Transcranial Magnetic Stimulation in the Treatment of depression: A Randomized, Double-blind, Placebo-controlled Trial. 2011 , 33, 35-44	15
1574	Improving the Quality of Psychiatric Care: Aligning Research, Policy, and Practice. 2011 , 9, 153-164	1
1573	Functional neuroimaging of treatment effects in psychiatry: methodological challenges and recommendations. 2012 , 122, 483-93	20
1572	Direct health care costs of treating seasonal affective disorder: a comparison of light therapy and fluoxetine. 2012 , 2012, 628434	7
1571	Depression treatment in patients with general medical conditions: results from the CO-MED trial. 2012 , 10, 23-33	28
1570	Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. 2012 , 9, e1001326	94
1569	Past, Present and Future Psychiatric Trends in USA: Lessons for All. 2012 , 22, 205-209	

1568	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. 2012 , 200, 130-6	18
1567	Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. 2012 , 26, 663-9	5
1566	Next-generation treatments for mental disorders. 2012 , 4, 155ps19	111
1565	Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis. 2012 , 20, 79-85	6
1564	Effects of electroconvulsive stimulation on long-term potentiation and synaptophysin in the hippocampus of rats with depressive behavior. 2012 , 28, 111-7	21
1563	Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. 2012 , 28, 157-61	78
1562	Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. 2012 , 32, 341-5	21
1561	A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. 2012 , 32, 551-7	152
1560	Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. 2012 , 32, 61-4	104
1559	Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. 2012 , 32, 479-86	27
1558	Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. 2012 , 32, 114-9	56
1557	PHQ-9 Response Curve: Rate of Improvement for Depression Treatment With Collaborative Care Management. 2012 , 3, 155-8	6
1556	Usefulness of symptom feedback to providers in an integrated primary care--mental health care clinic. 2012 , 63, 91-3	5
1555	Acute D-serine treatment produces antidepressant-like effects in rodents. 2012 , 15, 1135-48	61
1554	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. 2012 , 15, 589-600	152
1553	A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. <i>American Journal of Psychiatry</i> , 2012 , 169, 937-945	11.9 78
1552	Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior. 2012 , 2, e171	48
1551	Use of standard Webcam and Internet equipment for telepsychiatry treatment of depression among underserved Hispanics. 2012 , 63, 1213-7	64

1550	Reconsidering GHB: orphan drug or new model antidepressant?. 2012 , 26, 618-28	38
1549	Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. 2012 , 2, e129	34
1548	Sampling bias in an internet treatment trial for depression. 2012 , 2, e174	24
1547	Sobre el diagnóstico de bipolaridad. 2012 , 23, 543-551	
1546	Early switch strategy in patients with major depressive disorder. 2012 , 12, 1185-8	7
1545	Which therapy for which patient?. 2012 , 108-119	
1544	Neurochemical imaging and depressive behaviours. 2013 , 14, 101-34	8
1543	A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 2012 , 81, 87-97	99
1542	Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?. 2012 , 34, 56-60	14
1541	Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. 2012 , 81, 226-34	45
1540	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. 2012 , 42, 967-80	229
1539	Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. 2012 , 42, 1131-49	46
1538	A practical approach to the early identification of antidepressant medication non-responders. 2012 , 42, 309-16	13
1537	Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. 2012 , 15, 1413-25	79
1536	Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design. 2012 , 27, 100-6	21
1535	Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. 2012 , 27, 151-8	11
1534	Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?. 2012 , 27, 134-41	2
1533	Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study. 2012 , 69, 166-76	187

1532	Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression?. 2012 , 10, 139-58	21
1531	Feasibility of nurse-led antidepressant medication management of depression in an HIV clinic in Tanzania. 2012 , 43, 105-17	26
1530	Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. 2012 , 27, 1-7	27
1529	Surrogate markers of treatment outcome in major depressive disorder. 2012 , 15, 841-54	18
1528	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. 2012 , 15, 1387-99	18
1527	Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study. 2012 , 35, 1153-61	53
1526	The Long-Term Management of Major Depressive Disorders. 2012 , 10, 434-441	2
1525	Insulin resistance in major depressive disorder and the effects of psychotropic medications. 2012 , 9, 579-589	1
1524	Bibliography: Depression and Dysthymia. 2012 , 10, 481-483	
1523	How Do People Taking Psychiatric Drugs Explain Their "Chemical Imbalance"? 2012 , 13, 176-189	10
1522	Measurement-Based Care in the Treatment of Clinical Depression. 2012 , 10, 428-433	6
1521	Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. 2012 , 57, 782-8	23
1520	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. 2012 , 10, 492-505	1
1519	What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. 2012 , 10, 510-517	
1518	Prediction of longer-term outcome of treatment-resistant depression in tertiary care. 2012 , 201, 369-75	50
1517	Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. 2012 , 37, 2093-100	96
1516	Rediscovering trazodone for the treatment of major depressive disorder. 2012 , 26, 1033-49	109
1515	Aldosterone synergizes with peripheral inflammation to induce brain IL-1 β expression and depressive-like effects. 2012 , 60, 749-54	19

1514	5-HT2 ligands in the treatment of anxiety and depression. 2012 , 21, 1701-25	39
1513	P.2.c.012 Predictors of response and remission during an open-label, 10-week trial with selegiline transdermal system. 2012 , 22, S256-S257	
1512	P.2.c.013 Efficacy and safety of selegiline transdermal system for atypical depression: pooled analysis of short-term placebo-controlled trials. 2012 , 22, S257-S258	
1511	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. 2012 , 22, 183-99	48
1510	Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. 2012 , 22, 347-55	31
1509	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. 2012 , 22, 239-58	238
1508	Research planning for the future of psychiatric diagnosis. 2012 , 27, 553-6	17
1507	Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg. 2012 , 27, 250-7	3
1506	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. 2012 , 27, 114-28	27
1505	Symptom specificity in the acute treatment of Major Depressive Disorder: a re-analysis of the treatment of depression collaborative research program. 2012 , 137, 87-97	14
1504	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. 2012 , 46, 1406-13	93
1503	Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. 2012 , 530, 103-7	13
1502	A pilot study of acupuncture monotherapy in patients with major depressive disorder. 2012 , 141, 469-73	18
1501	Strategies to improve the management of depression in primary care. 2012 , 39, 415-31	107
1500	Treatment-resistant depression increases health costs and resource utilization. 2012 , 34, 379-88	24
1499	Factors associated with depression treatment-response in an outpatient psychosomatic medicine practice: an exploratory retrospective study. 2012 , 53, 387-91	3
1498	[Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part II: General Aspects of Treatment, Management of the Acute Phase, Continuation and Maintenance of Patients with a Depression Diagnosis]. 2012 , 41, 740-73	2
1497	How (not what) to prescribe: nonpharmacologic aspects of psychopharmacology. 2012 , 35, 143-63	28

1496	Etiology of depression: genetic and environmental factors. 2012 , 35, 51-71	130
1495	Feasibility and acceptability of clinic-based telepsychiatry for low-income Hispanic primary care patients. 2012 , 18, 297-304	68
1494	Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response. 2012 , 4, 52	9
1493	Cognitive mechanisms of treatment in depression. 2012 , 37, 117-36	319
1492	Ketamine for treatment-resistant unipolar depression: current evidence. 2012 , 26, 189-204	170
1491	Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. 2012 , 91, 201-14	49
1490	The hidden third: improving outcome in treatment-resistant depression. 2012 , 26, 587-602	49
1489	Will gene-environment interactions explain differential antidepressant response?. 2012 , 9, 319-322	7
1488	The development of a psychoanalytic outcome study: choices, conflicts, and consensus. 2012 , 60, 311-35	5
1487	Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. 2012 , 62, 63-77	669
1486	Signaling pathways underlying the rapid antidepressant actions of ketamine. 2012 , 62, 35-41	373
1485	Short-term individual housing induced social deficits in female Mongolian gerbils: attenuation by chronic but not acute imipramine. 2012 , 62, 1993-8	6
1484	The neurobiology of the EEG biomarker as a predictor of treatment response in depression. 2012 , 63, 507-13	118
1483	Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. 2012 , 35, 47-56	464
1482	Depression and epilepsy, pain and psychogenic non-epileptic seizures: clinical and therapeutic perspectives. 2012 , 24, 169-81	71
1481	Is there anything really novel on the antidepressant horizon?. 2012 , 14, 643-9	52
1480	The nicotinic acetylcholine receptor as a target for antidepressant drug development. 2012 , 2012, 104105	32
1479	Synaptic dysfunction in depression: potential therapeutic targets. 2012 , 338, 68-72	816

1478	Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression. 2012 , 79, 222-5	27
1477	Overcoming the problem of diagnostic heterogeneity in applying measurement-based care in clinical practice: the concept of psychiatric vital signs. 2012 , 53, 117-24	9
1476	Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse. 2012 , 33, 29-37	14
1475	Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: the CoBaIT randomised controlled trial protocol. 2012 , 33, 312-9	27
1474	Self-report and clinician-rated measures of depression severity: can one replace the other?. 2012 , 29, 1043-9	123
1473	Predictors of remission in depression to individual and combined treatments (PREdICT): study protocol for a randomized controlled trial. 2012 , 13, 106	72
1472	Knowledge of undisclosed corporate authorship ("ghostwriting") reduces the perceived credibility of antidepressant research: a randomized vignette study with experienced nurses. 2012 , 5, 490	2
1471	Abstracts of Invited Lectures. 2012 , 4, 1-62	2
1470	Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. 2012 , 72, 1313-33	143
1469	Pharmacogenetics in Psychiatry. 2012 , 215-250	
1468	Rapid-acting antidepressant strategies: mechanisms of action. 2012 , 15, 695-713	54
1467	CHAPTER 10:Glutamate Approaches Towards the Treatment of Mood Disorders. 2012 , 258-275	
1466	[Increased morbidity and use of Primary Care medical services in patients with major depressive disorder and their families: a retrospective cohort study]. 2012 , 44, 471-7	1
1465	Determining remission from depression on two self-report symptom scales: a comparison of the Quick Inventory of Depressive Symptomatology and the Clinically Useful Depression Outcome Scale. 2012 , 53, 1034-8	6
1464	Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor. 2012 , 223, 219-24	26
1463	Green tea polyphenols produce antidepressant-like effects in adult mice. 2012 , 65, 74-80	111
1462	Considerations on safety concerns about citalopram prescribing. 2012 , 87, 1042-5	16
1461	Methoxetamine: from drug of abuse to rapid-acting antidepressant. 2012 , 79, 504-7	32

1460 Molecular Imaging of Mood Episodes. **2012**, 273-303

1459 Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. **2012**, 12, 78-85 25

1458 Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment. **2012**, 91, 298-302 8

1457 Evidence-based somatic treatment of depression in adults. **2012**, 35, 131-42 8

1456 Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. **2012**, 22, 858-66 41

1455 Feasible evidence-based strategies to manage depression in primary care. **2012**, 14, 370-5 7

1454 Antidepressants and Major Depressive Disorder. **2012**,

1453 A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. **2012**, 367, 2475-84 213

1452 The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice. **2012**, 12, 192 19

1451 Cost-effectiveness of family psychoeducation to prevent relapse in major depression: results from a randomized controlled trial. **2012**, 12, 40 20

1450 Vilazodone: a novel antidepressant. **2012**, 69, 1551-7 19

1449 Toward a neurobiology of unrealistic optimism. **2012**, 3, 344 6

1448 A comparative, developmental, and clinical perspective of neurobehavioral sexual dimorphisms. **2012**, 6, 84 21

1447 Deep Brain Stimulation for Treatment-Resistant Depression: A State-of-the-Art Review. **2012**,

1446 Pharmacogenetics in psychiatry. 53-68 2

1445 Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. **2012**, 66, 435-44 29

1444 Pharmacology and neuroimaging of antidepressant action. **2012**, 106, 643-55

1443 Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. **2012**, 18, 1232-9 80

1442	Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. 2012 , 32, 234-43	14
1441	Further evidence that the cutoff to define remission on the 17-item Hamilton Depression Rating Scale should be lowered. 2012 , 29, 159-65	32
1440	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. 2012 , 29, 94-101	20
1439	Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. 2012 , 29, 111-22	13
1438	Comprehensive review of factors implicated in the heterogeneity of response in depression. 2012 , 29, 340-54	54
1437	Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians. 2012 , 29, 865-73	35
1436	Gene-environment interaction in major depression and antidepressant treatment response. 2012 , 14, 129-37	65
1435	New perspectives on glutamate receptor antagonists as antidepressants. 2012 , 35, 573-7	6
1434	Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains. 2012 , 221, 297-315	39
1433	Linderung depressiver Symptomatik. 2012 , 57, 241-247	
1432	Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. 2012 , 165, 289-312	135
1431	Effects of heart disease on depression treatment: results from the COMED study. 2012 , 34, 24-34	4
1430	Are patient characteristics associated with quality of depression care and outcomes in collaborative care programs for depression?. 2012 , 34, 1-8	12
1429	Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. 2012 , 34, 192-200	7
1428	Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in MEasurement-based Treatment (COMET) trial. 2012 , 34, 105-12	22
1427	Staging methods for treatment resistant depression. A systematic review. 2012 , 137, 35-45	133
1426	The association between sunshine duration and paroxetine response time in patients with major depressive disorder. 2012 , 136, 1067-71	8
1425	Calibration of response and remission cut-points on the Beck Depression Inventory-Second Edition for monitoring seasonal affective disorder treatment outcomes. 2012 , 138, 123-7	19

1424	Low trait anxiety, high resilience, and their interaction as possible predictors for treatment response in patients with depression. 2012 , 137, 61-9	52
1423	Augmenting antidepressant medication treatment of depressed women with emotionally focused therapy for couples: a randomized pilot study. 2012 , 38 Suppl 1, 23-38	50
1422	Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder. 2012 , 18, 441-51	30
1421	Estimation of the total number of hippocampal CA1 pyramidal neurons: new methodology applied to helpless rats. 2012 , 205, 130-8	9
1420	Sub-chronic dietary tryptophan depletion--an animal model of depression with improved face and good construct validity. 2012 , 46, 239-47	28
1419	Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. 2012 , 46, 375-81	56
1418	MicroRNAs and depression. 2012 , 46, 272-8	71
1417	Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. 2012 , 100, 601-6	68
1416	Novel glutamatergic agents for major depressive disorder and bipolar disorder. 2012 , 100, 678-87	65
1415	A comparison of four different approaches to measuring health utility in depressed patients. 2013 , 11, 81	24
1414	Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial. 2013 , 14, 105	3
1413	Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression. 2013 , 23, 1541-50	28
1412	Neurogenetics of depression: a focus on reward processing and stress sensitivity. 2013 , 52, 12-23	74
1411	New paradigms for treatment-resistant depression. 2013 , 1292, 21-31	82
1410	Bipolar disorder diagnosis: challenges and future directions. 2013 , 381, 1663-71	339
1409	Behavioral Neurobiology of Depression and Its Treatment. 2013 ,	3
1408	Influence of sociodemographic and socioeconomic features on treatment outcome in RCTs versus daily psychiatric practice. 2013 , 48, 975-84	10
1407	Treatment resistant depression: strategies for primary care. 2013 , 15, 370	13

1406	Towards translational rodent models of depression. 2013 , 354, 141-53	45
1405	Clinical issues in use of atypical antipsychotics for depressed patients. 2013 , 27 Suppl 1, S39-45	18
1404	mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. 2013 , 66, 40-52	94
1403	Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy. 2013 , 67, 219-27	11
1402	A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. 2013 , 67, 304-17	111
1401	Trajectories of individual symptoms in remitters versus non-remitters with depression. 2013 , 151, 506-513	28
1400	Treating the depressions with superficial brain stimulation methods. 2013 , 116, 399-413	13
1399	Race, genetic ancestry and response to antidepressant treatment for major depression. 2013 , 38, 2598-606	27
1398	Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. 2013 , 27, 703-16	204
1397	Personalized medicine in Alzheimer's disease and depression. 2013 , 36, 616-23	14
1396	Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. 2013 , 381, 375-84	223
1395	Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. 2013 , 144, 153-9	58
1394	The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. 2013 , 37, 1597-610	75
1393	Ketamine, sleep, and depression: current status and new questions. 2013 , 15, 394	51
1392	Study protocol for the randomised controlled trial: antigluocorticoid augmentation of anti-Depressants in Depression (The ADD Study). 2013 , 13, 205	6
1391	Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. 2013 , 14, 224	31
1390	Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. 2013 , 10, 142	128
1389	A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. 2013 , 74, 7-14	113

1388	Neuronal network plasticity and recovery from depression. 2013 , 70, 983-9	114
1387	Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. 2013 , 3, e242	89
1386	Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. 2013 , 13, 456-63	56
1385	A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder. 2013 , 124, 1975-85	100
1384	The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. 2013 , 13, 1161-82	4
1383	Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment. 2013 , 25, 572-8	14
1382	Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray?. 2013 , 30, 1137-44	13
1381	Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. 2013 , 27, 740-58	25
1380	Predictors of depressive symptoms at hospital discharge in patients with major depressive disorder. 2013 , 17, 144-7	0
1379	Multi-modality: a new approach for the treatment of major depressive disorder. 2013 , 16, 1433-1442	29
1378	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. 2013 , 13, 751-4	1
1377	Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). 2013 , 34, 136-44	22
1376	A new type of scale for determining remission from depression: the Remission from Depression Questionnaire. 2013 , 47, 78-82	37
1375	The failure of the antidepressant drug discovery process is systemic. 2013 , 27, 407-13; discussion 413-6	38
1374	GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. 2013 , 38, 729-42	223
1373	Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. 2013 , 242, 76-83	27
1372	Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. 2013 , 74, 250-6	498
1371	The clinical effectiveness of evidence-based interventions for depression: a pragmatic trial in routine practice. 2013 , 145, 349-55	26

1370	The activation of adenosine monophosphate-activated protein kinase in rat hippocampus contributes to the rapid antidepressant effect of ketamine. 2013 , 253, 305-9	31
1369	Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and bipolar depression. 2013 , 207, 143-9	26
1368	Brain, networks, depression, and more. 2013 , 23, 55-62	41
1367	Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. 2013 , 28, 221-6	60
1366	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. 2013 , 23, 895-901	20
1365	Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. 2013 , 23, 612-21	22
1364	Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach. 2013 , 2, 171-180	5
1363	Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats. 2013 , 253, 206-11	15
1362	Clinical features and drug induced side effects in early versus late antidepressant responders. 2013 , 47, 1309-18	24
1361	Prevention of recurrence of major depression among emerging adults by a group cognitive-behavioral/interpersonal intervention. 2013 , 147, 425-30	9
1360	Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. 2013 , 44, 23-8	174
1359	Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. 2013 , 149, 319-25	26
1358	Clinical doses of citalopram or reboxetine differentially modulate passive and active behaviors of female Wistar rats with high or low immobility time in the forced swimming test. 2013 , 110, 89-97	11
1357	Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. 2013 , 28, 362-71	24
1356	Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. 2013 , 74, 742-9	198
1355	Marked reductions in visual evoked responses but not ß-aminobutyric acid concentrations or ß-band measures in remitted depression. 2013 , 73, 691-8	24
1354	Stress-induced anhedonia correlates with lower hippocampal serotonin transporter protein expression. 2013 , 1513, 127-34	24
1353	Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. 2013 , 37, 1786-800	45

1352	A clinically useful social anxiety disorder outcome scale. 2013 , 54, 758-65	15
1351	Prediction of antidepressant treatment response from gray matter volume across diagnostic categories. 2013 , 23, 1503-15	33
1350	Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. 2013 , 74, 287-95	71
1349	Protective effects of ascorbic acid on behavior and oxidative status of restraint-stressed mice. 2013 , 49, 68-79	66
1348	Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. 2013 , 19, 337-44	218
1347	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. 2013 , 263, 385-91	12
1346	Genetics of Treatment-resistant Depression. 2013 , 43-90	1
1345	Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. 2013 , 52, 75-83	241
1344	Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants. 2013 , 343-411	1
1343	Opioid receptors: distinct roles in mood disorders. 2013 , 36, 195-206	337
1342	The neurobiology of depression and antidepressant action. 2013 , 37, 2331-71	315
1341	Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans. 2013 , 368, 20120192	22
1340	Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics?. 2013 , 81, 10-4	3
1339	Association between antidepressant side effects and functional impairment in patients with major depressive disorders. 2013 , 210, 127-33	15
1338	A genome-wide association study of a sustained pattern of antidepressant response. 2013 , 47, 1157-65	45
1337	Oscillatory serotonin function in depression. 2013 , 67, 801-20	18
1336	Rapid antidepressant effects: moving right along. 2013 , 18, 856-63	26
1335	Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective $\alpha 7$ -nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II. 2013 , 56, 5495-504	16

1334	The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. 2013 , 22, 219-29	20
1333	Pharmacogenetics in major depression: a comprehensive meta-analysis. 2013 , 45, 183-94	148
1332	Lithium augmentation of the effects of desipramine in a mouse model of treatment-resistant depression: a role for hippocampal cell proliferation. 2013 , 228, 36-46	21
1331	Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. 2013 , 22, 121-31	30
1330	Pharmacogenomics and Personalized Medicine in Mood Disorders. 2013 , 309-334	
1329	Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresi3n mayor: Revisi3n de la literatura. 2013 , 20, 2-7	1
1328	Teaching all the evidence bases: reintegrating psychodynamic aspects of prescribing into psychopharmacology training. 2013 , 41, 13-37	4
1327	Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. 2013 , 18, 1119-24	137
1326	Psychological therapies for treatment-resistant depression in adults. 2013 ,	2
1325	Gene x Environment interactions in the prediction of response to antidepressant treatment. 2013 , 16, 701-11	20
1324	Workplace depression: personalize, partner, or pay the price. <i>American Journal of Psychiatry</i> , 2013 , 170, 578-81	11.9 11
1323	Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys. 2013 , 38, 2666-74	50
1322	Biomarkers predicting antidepressant treatment response: how can we advance the field?. 2013 , 35, 23-31	62
1321	The treatment of depressed chinese americans using qigong in a health care setting: a pilot study. 2013 , 2013, 168784	10
1320	Yueju pill rapidly induces antidepressant-like effects and acutely enhances BDNF expression in mouse brain. 2013 , 2013, 184367	43
1319	Personalized psychiatry: many questions, fewer answers. 2013 , 38, 363-5	22
1318	Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study. 2013 , 17, 35-43	7
1317	Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. 2013 , 75, 863-72	34

1316	Evidence-based recommendations for the prescription of exercise for major depressive disorder. 2013 , 19, 204-12		74
1315	Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. 2013 , 28, 322-9		8
1314	The neurobiology of depression--revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies. 2013 , 368, 20120535		61
1313	A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. 2013 , 3, 151-61		20
1312	Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. 2013 , 18, 322-32		23
1311	Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. <i>American Journal of Psychiatry</i> , 2013 , 170, 207-17	11.9	181
1310	Moderators of outcome in late-life depression: a patient-level meta-analysis. <i>American Journal of Psychiatry</i> , 2013 , 170, 651-9	11.9	57
1309	Parameters of education and the course of depression: an analysis in the Turkish sociocultural context. 2013 , 59, 318-31		5
1308	Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. 2013 , 33, 38-44		10
1307	Use of mental health telemetry to enhance identification and predictive value of early changes during augmentation treatment of major depression. 2013 , 33, 775-81		13
1306	Pharmacogenetics of mood disorders: what clinicians need to know. 2013 , 18, 272-84		9
1305	Majör Depresif Bozuklukta Dışelmenin Eđelmenleri. 2013 , 50, 122-129		2
1304	NMDA Receptor Antagonists for Treatment of Depression. 2013 , 6, 480-99		39
1303	Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data. 2013 , 47, 933-45		10
1302	Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. 2013 , 43, 945-60		34
1301	The efficacy of interpersonal psychotherapy for depression among economically disadvantaged mothers. 2013 , 25, 1065-78		33
1300	Possible usefulness of tianeptine in treatment-resistant depression. 2013 , 17, 313-6		8
1299	Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. 2013 , 28, 925-32		16

1298	Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline?. 2013 , 27, 719-31	19
1297	Predictive socioeconomic and clinical profiles of antidepressant response and remission. 2013 , 30, 624-30	36
1296	The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study. 2013 , 128, 271-81	16
1295	Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. 2013 , 346, f2570	103
1294	Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder. 2013 , 28, 576-85	4
1293	Increase in work productivity of depressed individuals with improvement in depressive symptom severity. <i>American Journal of Psychiatry</i> , 2013 , 170, 633-41	11.9 84
1292	A review of current evidence for vilazodone in major depressive disorder. 2013 , 17, 160-9	23
1291	Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. 2013 , 18, 1236-41	77
1290	The effects of congenital brain serotonin deficiency on responses to chronic fluoxetine. 2013 , 3, e291	35
1289	Behavioral and neurobiological effects of deep brain stimulation in a mouse model of high anxiety- and depression-like behavior. 2013 , 38, 1234-44	56
1288	Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. 2013 , 16, 958-65	102
1287	Treatment as usual (TAU) for depression: a comparison of psychotherapy, pharmacotherapy, and combined treatment at a large academic medical center. 2013 , 50, 110-8	12
1286	Pharmacological interventions for treatment-resistant depression in adults. 2013 ,	3
1285	T-lymphocyte CREB as a potential biomarker of response to antidepressant drugs. 2013 , 16, 967-74	7
1284	Personality, Psychopathology, and the Neurotransmitter Attributes Questionnaire (NAQ). 2013 , 3, 215824401349254	34
1283	N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression. 2013 , 33, 719-20	22
1282	Mechanisms of antidepressant resistance. 2013 , 4, 146	71
1281	Epigenetic Modulation of Mood Disorders. 2013 , 4,	14

1280	Novel glutamatergic drugs for the treatment of mood disorders. 2013 , 9, 1101-12	68
1279	Mood disorders and complementary and alternative medicine: a literature review. 2013 , 9, 639-58	88
1278	Agomelatine as monotherapy for major depression: an outpatient, open-label study. 2013 , 9, 1595-604	2
1277	Which drug for which patient? Is there a fluoxetine responding versus a bupropion responding personality profile?. 2013 , 9, 142-7	6
1276	Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. 2013 , 19, 1898-922	54
1275	Pediatric anxiety disorders: from neuroscience to evidence-based clinical practice. 2013 , 35 Suppl 1, S03-21	23
1274	Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D. 2013 , 8, e55239	6
1273	Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. 2013 , 8, e62226	62
1272	Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?. 2013 , 4, 110	81
1271	Yoga on our minds: a systematic review of yoga for neuropsychiatric disorders. 2012 , 3, 117	200
1270	Treating depression and depression-like behavior with physical activity: an immune perspective. 2013 , 4, 3	81
1269	The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. 2013 , 2013, 805497	104
1268	Combining medication and psychotherapy in the treatment of depression. 299-310	
1267	Management of adult major depressive disorder. 37-58	
1266	Cognitive behavior therapy. 258-269	
1265	Brain imaging. 358-367	
1264	Pharmacogenetics and mood disorders. 368-379	
1263	What Treatments Are Effective for Depression in the Palliative Care Setting?. 2013 , 181-190	

1262	Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). 2014 , 75, e1428-32	99
1261	Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. 2014 , 9, e98118	228
1260	EMSAM (deprenyl patch): how a promising antidepressant was underutilized. 2014 , 10, 1911-23	13
1259	Effectiveness of the relaxation response-based group intervention for treating depressed chinese american immigrants: a pilot study. 2014 , 11, 9186-201	8
1258	A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. 2014 , 8, 189	58
1257	Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. 2014 , 8, 199	172
1256	Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders. 2014 , 8, 440	13
1255	Mental health: depression needs large human-genetics studies. 2014 , 515, 189-91	30
1254	Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study. 2014 , 10, 631-9	10
1253	Treatment and outcomes for patients with depression who are partial responders to SSRI treatment: post-hoc analysis findings from the FINDER European observational study. 2014 , 169, 149-56	5
1252	Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. 2014 , 17, 393-405	42
1251	A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. 2014 , 65, 977-87	308
1250	Optimization of Treatment Algorithms for Clinical Depression: Glutamate Antagonists and Transcranial Magnetic Stimulation as Case Examples. 2014 , 12, 146-151	1
1249	Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBaT Trial. 2014 , 204, 69-76	19
1248	Deep brain stimulation for treatment-resistant depression. 2014 , 64-75	1
1247	Desvenlafaxine for the treatment of major depressive disorder. 2014 , 15, 1449-63	10
1246	Pharmacotherapy of postpartum depression: an update. 2014 , 15, 1223-34	45
1245	Fresh approaches to antidepressant drug discovery. 2014 , 9, 407-21	5

1244	Epigenetics of depression. 2014 , 128, 103-37	22
1243	Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. 2014 , 44, 225-39	311
1242	Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. 2014 , 39, 973-80	44
1241	Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. 2014 , 39, 2549-59	30
1240	Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. 2014 , 95, 154-67	138
1239	Treatment of depression: men and women are different?. <i>American Journal of Psychiatry</i> , 2014 , 171, 384-71.9	13
1238	Optimizing the management of depression: primary care experience. 2014 , 220 Suppl 1, S45-57	27
1237	Rapid anxiolytic effects of a 5-HT _{1A} receptor agonist are mediated by a neurogenesis-independent mechanism. 2014 , 39, 1366-78	96
1236	Electroconvulsive therapy mediates neuroplasticity of white matter microstructure in major depression. 2014 , 4, e380	86
1235	Synthesis and Antimicrobial Screening of Novel 4-Substituted Phenyl-5-[1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl]-2H-1,2,4-triazole-3-thiones. 2014 , 2014, 439243	1
1234	Food for thought: understanding the value, variety and usage of management algorithms for major depressive disorder. 2014 , 220 Suppl 1, S3-14	4
1233	Behavior Genetics of Psychopathology. 2014 ,	
1232	The link between stress disorders and autonomic dysfunction in muscular dystrophy. 2014 , 5, 25	11
1231	Impact of acute administration of escitalopram on the processing of emotional and neutral images: a randomized crossover fMRI study of healthy women. 2014 , 39, 267-75	17
1230	Neither cytochrome P450 family genes nor neuroendocrine factors could independently predict the SSRIs treatment in the Chinese Han population. 2014 , 47, 60-6	5
1229	How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. 2014 , 29, 528-36	6
1228	Rational site-directed pharmacotherapy for major depressive disorder. 2014 , 17, 997-1008	17
1227	Impact of fatigue on outcome of selective serotonin reuptake inhibitor treatment: secondary analysis of STAR*D. 2014 , 30, 2109-18	20

1226	Treatment of depression in a former smoker with varenicline? A case report and discussion. 2014 , 26, 172-5	1
1225	Toward personalizing treatment for depression: predicting diagnosis and severity. 2014 , 21, 1069-75	67
1224	Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study): study protocol for a randomised clinical trial. 2014 , 4, e006359	10
1223	The remission from depression questionnaire as an outcome measure in the treatment of depression. 2014 , 31, 533-8	17
1222	Evidence behind FDA alerts for drugs with adverse cardiovascular effects: implications for clinical practice. 2014 , 34, 358-72	1
1221	Cognitive-emotional training as an intervention for major depressive disorder. 2014 , 31, 699-706	41
1220	GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. 2014 , 15, 1451-9	21
1219	Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder. 2014 , 165B, 77-83	13
1218	Neuropsychological function before and after subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression. 2014 , 31, 690-8	22
1217	Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. 2014 , 29, 1132-9	73
1216	Clinical relevance of fatigue as a residual symptom in major depressive disorder. 2014 , 31, 250-7	83
1215	Predominant role of plasma membrane monoamine transporters in monoamine transport in 1321N1, a human astrocytoma-derived cell line. 2014 , 129, 591-601	24
1214	Psychiatric genetics and the future of personalized treatment. 2014 , 31, 893-8	13
1213	Predictors of length of hospital stay for patients with late-onset depression in Japan. 2014 , 14, 124-31	3
1212	Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates. 2014 , 4, e486	50
1211	Classification of major depressive disorder subjects using Pre-rTMS electroencephalography data with support vector machine approach. 2014 ,	2
1210	Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. 2014 , 10, 759-66	5
1209	A model for streamlining psychotherapy in the RDoC era: the example of 'Engage'. 2014 , 19, 14-9	64

1208	Neuromodulation Therapies in the Elderly Depressed Patient. 2014 , 3, 229-236	3
1207	Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis. 2014 , 3, 133	5
1206	Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. 2014 , 29, 86-92	20
1205	Prevention of common mental disorders: conceptual framework and effective interventions. 2014 , 27, 294-301	6
1204	Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D. 2014 , 20, 178-87	14
1203	Baseline difference between patients' and clinicians' rated illness severity scores and subsequent outcomes in major depressive disorder: analysis of the sequenced treatment alternatives to relieve depression data. 2014 , 34, 297-302	9
1202	Comparison of physician-rating and self-rating scales for patients with major depressive disorder. 2014 , 34, 716-21	7
1201	Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. 2014 , 34, 313-7	37
1200	Antidepressant pharmacogenetics. 2014 , 27, 43-51	35
1199	Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. 2014 , 29, 197-205	20
1198	Safety of high-dosage citalopram. <i>American Journal of Psychiatry</i> , 2014 , 171, 20-2	11.9 8
1197	Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?. 2014 , 2014, 627863	36
1196	Antidepressant activity of aqueous extract of Phaseolus vulgaris (black bean) in rodent models of depression. 2014 , 4, 118	5
1195	Guide to Assessment Scales in Major Depressive Disorder. 2014 ,	1
1194	Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder. 2014 , 15, 135-44	18
1193	Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. 2014 , 13, 17	13
1192	Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. 2014 , 34, 57-65	16
1191	Genomewide interaction and enrichment analysis on antidepressant response. 2014 , 44, 753-65	5

1190	Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. 2014 , 19, 496-508	62
1189	Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. 2014 , 65, 267-300	56
1188	Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report. 2014 , 75, e23-6	18
1187	Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. 2014 , 163, 40-6	1
1186	Default mode network mechanisms of transcranial magnetic stimulation in depression. 2014 , 76, 517-26	365
1185	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). 2014 , 163, 18-24	30
1184	Predictive value of baseline resistance in early response to antidepressants. 2014 , 161, 127-35	3
1183	Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes. 2014 , 264, 213-23	21
1182	Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. 2014 , 231, 2299-310	11
1181	A review of current evidence for acetyl-L-carnitine in the treatment of depression. 2014 , 53, 30-7	64
1180	Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. 2014 , 31, 291-6	136
1179	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. 2014 , 231, 2921-31	45
1178	MIF: mood improving/inhibiting factor?. 2014 , 11, 11	35
1177	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. 2014 , 264, 567-75	31
1176	Brain galanin system genes interact with life stresses in depression-related phenotypes. 2014 , 111, E1666-73	71
1175	Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. 2014 , 162, 20-5	11
1174	Combination antidepressant therapy for major depressive disorder: speed and probability of remission. 2014 , 52, 7-14	25
1173	An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets. 2014 , 18, 159-76	45

1172	Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?. 2014 , 39, 1041-51	75
1171	Revitalizing psychiatric therapeutics. 2014 , 39, 220-9	61
1170	Morningness-eveningness and treatment response in major depressive disorder. 2014 , 31, 283-9	28
1169	Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man. 2014 , 123, 55-76	11
1168	NMDA receptor dysregulation in chronic state: a possible mechanism underlying depression with BDNF downregulation. 2014 , 79, 88-97	30
1167	Neuromodulation for treatment-refractory major depressive disorder. 2014 , 186, 33-9	26
1166	Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. 2014 , 4, e481	32
1165	Antidepressant-like and anxiolytic-like effects following activation of the μ -opioid receptor heteromer in the nucleus accumbens. 2014 , 19, 986-94	31
1164	Vortioxetine: a review of its use in major depressive disorder. 2014 , 28, 855-74	28
1163	Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS) in treatment-resistant major depression. 2014 , 15, 570-8	31
1162	Social defeat as an animal model for depression. 2014 , 55, 221-32	143
1161	Tricyclic antidepressants exhibit variable pharmacological profiles at the α_2A adrenergic receptor. 2014 , 451, 461-6	8
1160	Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. 2014 , 18, 567-77	14
1159	M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. 2014 , 351, 448-56	76
1158	A phase-specific neuroimmune model of clinical depression. 2014 , 54, 265-74	48
1157	A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. 2014 , 167, 215-23	10
1156	A clinically useful self-report measure of the DSM-5 mixed features specifier of major depressive disorder. 2014 , 168, 357-62	26
1155	A randomized controlled longitudinal naturalistic trial testing the effects of automatic self-transcending meditation on heart rate variability in late life depression: study protocol. 2014 , 14, 307	1

1154	INtegration of DEPression Treatment into HIV Care in Uganda (INDEPTH-Uganda): study protocol for a randomized controlled trial. 2014 , 15, 248	33
1153	Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype. 2014 , 5, 908-19	38
1152	The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study. 2014 , 48, 1115-25	13
1151	Perfusion deficits, inflammation and aging precipitate depressive behaviour. 2014 , 15, 439-48	49
1150	Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. 2014 , 19, 1106-14	66
1149	Antidepressant-like effect of <i>Canavalia brasiliensis</i> (ConBr) lectin in mice: evidence for the involvement of the glutamatergic system. 2014 , 122, 53-60	23
1148	Early switching strategies in antidepressant non-responders: current evidence and future research directions. 2014 , 28, 601-9	46
1147	What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment. 2014 , 13, 8	7
1146	The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy. 2014 , 18, 78-85	9
1145	Animal Models of Environmental Manipulations Resulting in Epigenetic Modifications That Increase Risk for Affective Disorders. 2014 , 181-205	3
1144	Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. 2014 , 162, 50-4	3
1143	A randomized controlled trial of intranasal ketamine in major depressive disorder. 2014 , 76, 970-6	277
1142	Heart rate variability and treatment outcome in major depression: a pilot study. 2014 , 93, 204-10	26
1141	St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract. 2014 , 30, S37-42	13
1140	Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. 2014 , 155, 123-9	138
1139	Long-term follow-up of bilateral anterior capsulotomy in patients with refractory obsessive-compulsive disorder. 2014 , 119, 91-5	32
1138	Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. 2014 , 215, 355-61	86
1137	Predictors of remission from chronic depression: a prospective study in a nationally representative sample. 2014 , 55, 463-7	15

1136	Is there a role for palmitoylethanolamide in the treatment of depression?. 2014 , 82, 507-11	8
1135	Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response. 2014 , 76, 542-9	100
1134	Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. 2014 , 24, 1269-78	13
1133	Does comorbid subthreshold anxiety predict treatment response in depression? Results from a naturalistic cohort study (the CRESCEND study). 2014 , 152-154, 352-9	9
1132	SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. 2014 , 22, 1140-8	15
1131	Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test. 2014 , 566, 172-6	19
1130	Akt mediates GSK-3 β phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions. 2014 , 21, 183-8	31
1129	Dysregulation of the hypothalamus-pituitary-adrenal axis predicts some aspects of the behavioral response to chronic fluoxetine: association with hippocampal cell proliferation. 2014 , 8, 340	22
1128	5-HT ₇ receptor signaling: improved therapeutic strategy in gut disorders. 2014 , 8, 396	20
1127	Mechanisms underlying the antidepressant response and treatment resistance. 2014 , 8, 208	58
1126	Eveningness and insomnia: independent risk factors of nonremission in major depressive disorder. 2014 , 37, 911-7	114
1125	Treating to target in major depressive disorder: response to remission to functional recovery. 2015 , 20 Suppl 1, 20-30; quiz 31	24
1124	Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. 2015 , 35, 706-10	9
1123	Neurotoxins: Expanding Uses of Neuromodulators in Medicine--Major Depressive Disorder. 2015 , 136, 111S-119S	11
1122	Effectiveness of the first French psychoeducational program on unipolar depression: study protocol for a randomized controlled trial. 2015 , 15, 294	1
1121	Plasma amino acid profiling in major depressive disorder treated with selective serotonin reuptake inhibitors. 2015 , 21, 417-24	31
1120	Seasonal variation in clinical remission of primary care patients with depression: impact of gender. 2015 , 21, 160-5	2
1119	Contribution of Diet and Exercise in the Pathogenesis of Major Depression. 2015 , 93-104	

1118 Antidepressant Research Controversies. **2015**, 1-6

1117 Psychiatric Features of Epilepsy and their Management. **2015**, 259-274

1116 The Effects of Escitalopram Treatment on Oxidative/ Antioxidative Parameters in Patients with Depression. **2015**, 25, 272-279 5

1115 The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. **2015**, 60, 9-13 24

1114 Pharmacological Management of Treatment-Resistant Unipolar Depression. **2015**, 2311-2330 1

1113 Phenomenology of Depression in Alzheimer's Disease. **2015**, 47, 845-55 46

1112 Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies. **2015**, 1, 145-55 46

1111 Long-Term, Open-Label, Safety Study of Edvoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment. **2015**, 35, 266-72 4

1110 Emotionale Verflachung unter antidepressiver Therapie. **2015**, 16, 38-42

1109 Biomarkers for Antidepressant Selection: iSPOT-D Study. **2015**, 2, 137-145 2

1108 Associations Between Pain, Current Tobacco Smoking, Depression, and Fibromyalgia Status Among Treatment-Seeking Chronic Pain Patients. **2015**, 16, 1433-42 30

1107 Affective Biases in Humans and Animals. **2016**, 263 16

1106 Adding smartphone-based cognitive-behavior therapy to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled trial. **2015**, 16, 293 16

1105 Mood disorders: neurocognitive models. **2015**, 17 Suppl 2, 3-20 43

1104 Is e-health the answer to gaps in adolescent mental health service provision?. **2015**, 28, 336-42 21

1103 ??????????????. **2015**, 12, 17-19

1102 Statistics Commentary Series: Commentary #10-Dealing With Drop-Outs. **2015**, 35, 496-8 1

1101 Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India. **2015**, s2,

1100	Levomilnacipran for the treatment of major depressive disorder: a review. 2015 , 11, 125-35	18
1099	Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. 2015 , 10, 49-62	15
1098	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. 2015 , 51, 66-80	11
1097	Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. 2015 , 13, 150-6	82
1096	Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study. 2015 , 11, 197-205	14
1095	Robust and sustained effect of ketamine infusions coadministered with conventional antidepressants in a patient with refractory major depression. 2015 , 2015, 815673	1
1094	The impact of the duration of an untreated episode on improvement of depression and somatic symptoms. 2015 , 11, 2245-52	8
1093	Toward an online cognitive and emotional battery to predict treatment remission in depression. 2015 , 11, 517-31	13
1092	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study. 2015 , 11, 3031-40	3
1091	Pre-stress performance in an instrumental training predicts post-stress behavioral alterations in chronically stressed rats. 2015 , 9, 119	2
1090	Glia in the cytokine-mediated onset of depression: fine tuning the immune response. 2015 , 9, 268	47
1089	Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders. 2015 , 9, 357	94
1088	A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine adjunct, placebo-controlled, pilot clinical study. 2015 , 11, 2013-21	17
1087	Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. 2015 , 11, 1193-212	13
1086	Structural MRI-Based Predictions in Patients with Treatment-Refractory Depression (TRD). 2015 , 10, e0132958	38
1085	Severity of Depression Predicts Remission Rates Using Transcranial Magnetic Stimulation. 2015 , 6, 114	13
1084	Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. 2015 , 13, 616-35	30
1083	Possible Involvement of μ Opioid Receptor in the Antidepressant-Like Effect of Shuyu Formula in Restraint Stress-Induced Depression-Like Rats. 2015 , 2015, 452412	4

1082	Rapid Antidepressant Activity of Ethanol Extract of <i>Gardenia jasminoides</i> Ellis Is Associated with Upregulation of BDNF Expression in the Hippocampus. 2015 , 2015, 761238	23
1081	Lessons Learned: Implementation of a Culturally Focused Psychiatric Consultation Service for Latino Americans and Asian Americans. 2015 , 26, 792-801	1
1080	Translational Perspectives in Treatment-Resistant Mood Disorders. 2015 , 13, 556-7	
1079	Deep Brain Stimulation for the Management of Treatment-Refractory Major Depressive Disorder. 2015 , 95-104	
1078	Exploring the role of drug-metabolising enzymes in antidepressant side effects. 2015 , 232, 2609-17	21
1077	Repeated Cortisol Awakening Response as Predictor of Antidepressant Treatment Outcome with Duloxetine. 2015 , 71, 97-102	6
1076	Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. 2015 , 18, pyv060	107
1075	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. 2015 , 29, 459-525	381
1074	Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. 2015 , 31, 1179-89	6
1073	Reduction of patient-reported antidepressant side effects, by type of collaborative care. 2015 , 66, 272-8	11
1072	The role of gender in moderating treatment outcome in collaborative care for anxiety. 2015 , 66, 265-71	19
1071	Hippocampal volume and the rapid antidepressant effect of ketamine. 2015 , 29, 591-5	50
1070	Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder. 2015 , 29, 565-74	3
1069	Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys. 2015 , 66, 455-62	24
1068	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. 2015 , 66-67, 84-94	28
1067	TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression. 2015 , 48, 95-103	10
1066	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. 2015 , 5, e687	17
1065	Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. 2015 , 25, 2289-99	7

1064	The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. 2015 , 37, 2309-2323.e6	13
1063	Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat. 2014 , 18,	9
1062	Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial. 2015 , 66, 1303-11	5
1061	Psychiatry Under the Influence. 2015 ,	95
1060	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. 2015 , 49, 1087-206	461
1059	A critical appraisal of the selegiline transdermal system for major depressive disorder. 2015 , 8, 673-81	8
1058	The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. 2015 , 29, 577-89	77
1057	A Novel Mixture Model to Estimate the Time to Drug Effect Onset and Its Association with Covariates. 2015 , 80, 90-9	
1056	Neurophysiological and Neurochemical Mechanisms Underlying Depression Disorders and Search for New Directions of Treatment. 2015 , 47, 348-361	
1055	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. 2015 , 2, 216-225	11
1054	Aldosterone Signals the Onset of Depressive Behaviour in a Female Rat Model of Depression along with SSRI Treatment Resistance. 2015 , 102, 274-287	23
1053	Rodent models of treatment-resistant depression. 2015 , 753, 51-65	30
1052	The cognitive neuropsychological model of antidepressant response. 2015 , 4, 124-130	4
1051	Tea consumption and the risk of depression: a meta-analysis of observational studies. 2015 , 49, 334-45	32
1050	Cognition as a target in major depression: new developments. 2015 , 25, 231-47	53
1049	Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. 2015 , 218, 21-31	63
1048	Developing cognitive-emotional training exercises as interventions for mood and anxiety disorders. 2015 , 30, 75-81	15
1047	Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. 2015 , 173, 126-33	17

1046	Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. 2015 , 277, 167-177		42
1045	Critical analysis of the efficacy of meditation therapies for acute and subacute phase treatment of depressive disorders: a systematic review. 2015 , 56, 140-52		37
1044	Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. <i>American Journal of Psychiatry</i> , 2015 , 172, 124-38	11.9	171
1043	The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. 2015 , 61, 1-12		90
1042	Mobile health monitoring to characterize depression symptom trajectories in primary care. 2015 , 174, 281-6		16
1041	Spine synapse remodeling in the pathophysiology and treatment of depression. 2015 , 601, 20-9		155
1040	Effect of Korean Red Ginseng as an adjuvant treatment for women with residual symptoms of major depression. 2015 , 7, 330-6		23
1039	Understanding the non-pharmacological correlates of self-reported efficacy of antidepressants. 2015 , 131, 434-45		19
1038	A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. 2015 , 40, 1332-42		71
1037	Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study. 2015 , 62, 31-7		11
1036	Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. 2015 , 232, 529-40		7
1035	Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects. 2015 , 45, 1073-92		55
1034	A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. 2015 , 232, 2061-70		66
1033	Cognitive dysfunction in depression - pathophysiology and novel targets. 2014 , 13, 1819-35		66
1032	Cognitive Behavioral Therapy for Depressed Adults with Mild Intellectual Disability: A Pilot Study. 2015 , 8, 72-97		21
1031	Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. 2015 , 186, 306-11		60
1030	Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. 2015 , 25, 1082-90		39
1029	Target-based biomarker selection - Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression. 2015 , 66-67, 24-37		31

1028	Review on EEG and ERP predictive biomarkers for major depressive disorder. 2015 , 22, 85-98	35
1027	The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. 2015 , 186, 358-66	52
1026	A patient-centered model of the action of psychotropic drugs. 2015 , 4, 46-53	1
1025	Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients. 2015 , 78, 579-84	4
1024	Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder. 2015 , 16, 6251-65	43
1023	Impact of non-remission of depression on costs and resource utilization: from the COMorbidities and symptoms of DEpression (CODE) study. 2015 , 31, 1165-77	22
1022	BDNF release is required for the behavioral actions of ketamine. 2014 , 18,	192
1021	Phytochemical constituents as future antidepressants: a comprehensive review. 2015 , 26, 699-719	82
1020	BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. 2015 , 16, 997-1013	33
1019	Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy. 2015 , 32, 213-20	14
1018	Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. 2015 , 175, 233-40	31
1017	Sex differences in glutamate receptor gene expression in major depression and suicide. 2015 , 20, 1057-68	111
1016	Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial. 2015 , 40, 2398-408	125
1015	Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. 2015 , 75, 577-87	180
1014	Blood transcriptomic markers for major depression: from animal models to clinical settings. 2015 , 1344, 37-49	13
1013	Behavioral and molecular responses to electroconvulsive shock differ between genetic and environmental rat models of depression. 2015 , 226, 451-60	12
1012	DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent antidepressant and antimanic activity. 2015 , 757, 11-20	14
1011	Antidepressant activity of fluoxetine in the zinc deficiency model in rats involves the NMDA receptor complex. 2015 , 287, 323-30	17

1010	Cordance derived from REM sleep EEG as a biomarker for treatment response in depression--a naturalistic study after antidepressant medication. 2015 , 63, 97-104	14
1009	A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. 2015 , 24, 281-90	17
1008	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , 2015 , 172, 743-50	11.9 106
1007	Group Metacognitive Therapy for Severe Antidepressant and CBT Resistant Depression: A Baseline-Controlled Trial. 2015 , 39, 14-22	34
1006	Vagus nerve stimulation for treatment-resistant mood disorders: a long-term naturalistic study. 2015 , 15, 64	18
1005	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. 2015 , 265, 5-18	19
1004	Adrenergic Receptor Trafficking as a Therapeutic Target in Antidepressant Drug Action. 2015 , 132, 207-25	12
1003	Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram. 2015 , 126, 1185-1189	77
1002	Effects of religiosity and spirituality on the treatment response in patients with depressive disorders. 2015 , 60, 26-34	15
1001	Genome-wide association studies in pharmacogenomics of antidepressants. 2015 , 16, 555-66	30
1000	A facile synthesis of N-substituted 2,5-dimethylpyrroles with saccharin as a green catalyst. 2015 , 51, 320-323	9
999	The benefit of combined acupuncture and antidepressant medication for depression: A systematic review and meta-analysis. 2015 , 176, 106-17	80
998	Is Population-Based Identification of Perinatal Depression and Anxiety Desirable?. 2015 , 11-31	6
997	Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. 2015 , 30, 504-10	19
996	Depression severity in electroconvulsive therapy (ECT) versus pharmacotherapy trials. 2015 , 31, 31-3	19
995	Immobility time during the forced swimming test predicts sensitivity to amitriptyline, whereas traveled distance in the circular corridor indicates resistance to treatment in female Wistar rats. 2015 , 26, 233-8	2
994	Brain Activation During Emotional Memory Processing Associated with Subsequent Course of Depression. 2015 , 40, 2454-63	15
993	Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. <i>American Journal of Psychiatry</i> , 2015 , 172, 950-66	11.9 384

992	Isn't It About Time to Employ Measurement-Based Care in Practice?. <i>American Journal of Psychiatry</i> , 2015 , 172, 934-6	11.9	28
991	Antidepressant-like effect of the water extract of the fixed combination of <i>Gardenia jasminoides</i> , <i>Citrus aurantium</i> and <i>Magnolia officinalis</i> in a rat model of chronic unpredictable mild stress. 2015 , 22, 1178-85		28
990	A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. 2015 , 40, 1-6		16
989	Role of Leadership in Narrowing the Gap between Science and Practice: Improving Treatment Outcomes at the Systems Level. 2015 , 86, 311-23		8
988	Translating depression biomarkers for improved targeted therapies. 2015 , 59, 1-15		17
987	[Ketamine--a new treatment option for therapy-resistant depression]. 2015 , 83, 91-7		4
986	Principal Component Analysis applied to the identification of spectral variations in depressed mouse brain. 2015 ,		
985	Personalized Medicine and Mood Disorders. 2015 , 38, 395-403		22
984	Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. <i>American Journal of Psychiatry</i> , 2015 , 172, 1004-13	11.9	149
983	Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. 2015 , 128, S1-S15		45
982	Long term sertraline effects on neural structures in depressed and nondepressed adult female nonhuman primates. 2015 , 99, 369-78		15
981	Treatment-resistant depression: are animal models of depression fit for purpose?. 2015 , 232, 3473-95		87
980	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. 2015 , 5, e509		65
979	Universal depression screening, diagnosis, management, and outcomes at a student-run free clinic. 2015 , 39, 259-66		21
978	The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. 2015 , 229, 760-70		15
977	A genome-wide association study of antidepressant response in Koreans. 2015 , 5, e633		23
976	A neurocognitive model for understanding treatment action in depression. 2015 , 370, 20140213		42
975	The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. 2015 , 188, 270-7		26

974	A potential role for the acid-sensing T cell death associated gene-8 (TDAG8) receptor in depression-like behavior. 2015 , 150, 78-82	6
973	Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. 2015 , 20, 148-56	18
972	Influence of Val108/158Met COMT Gene Polymorphism on the Efficacy of Modified Electroconvulsive Therapy in Patients with Treatment Resistant Depression. 2015 , 71, 1387-93	11
971	Theta-burst stimulation: a new form of TMS treatment for depression?. 2015 , 32, 182-92	88
970	ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. 2015 , 15, 332-9	22
969	Ketamine and other potential glutamate antidepressants. 2015 , 225, 1-13	69
968	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. 2015 , 174, 157-64	16
967	Developments in the field of antidepressants, where do we go now?. 2015 , 25, 657-70	63
966	Using Measurement-Based Care to Enhance Any Treatment. 2015 , 22, 49-59	183
965	Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. 2015 , 56, 329-37	30
964	Integrating the monoamine, neurotrophin and cytokine hypotheses of depression--a central role for the serotonin transporter?. 2015 , 147, 1-11	99
963	Neurosurgical Treatments for Psychiatric Disorders. 2015 ,	2
962	Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis. 2015 , 20, 311-9	153
961	A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. 2015 , 57, 11-6	69
960	The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder. 2015 , 46, 277-84	12
959	Faster, better, stronger: towards new antidepressant therapeutic strategies. 2015 , 753, 32-50	65
958	The promise of psychiatric pharmacogenomics. 2015 , 77, 29-35	40
957	Risk factors for treatment resistance in unipolar depression: a systematic review. 2015 , 171, 137-41	74

956	A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. 2015 , 122, 465-75	3
955	Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor. 2015 , 56, 254-63	34
954	The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data. 2015 , 265, 73-82	21
953	Repetitive Transcranial Magnetic Stimulation in Major Depression. 2016 , 07,	
952	Editorial (Thematic Selection: Inflammatory and Immune Responses in Depression). 2016 , 14, 663-4	
951	The interactive effects of ketamine and magnesium upon depressive-like pathology. 2016 , 12, 2049-56	3
950	Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. 2016 , 12, 2755-2764	6
949	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. 2016 , 77, 1036-42	12
948	Comparison of the Effectiveness of Cognitive Behavioral Therapy and Neurofeedback: Reducing Insomnia Symptoms. 2016 , 9, 35	2
947	Nutraceuticals Neuroprotect Naturally. 2016 , 373-397	3
946	Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications. 2016 , 16, 206-15	44
945	MedLink: A mobile intervention to improve medication adherence and processes of care for treatment of depression in general medicine. 2016 , 2, 2055207616663069	16
944	The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. 2016 , 12, 523-31	5
943	Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. 2016 , 14, 721-31	216
942	The Treatment with Exercise Augmentation for Depression (TREAD) study. 96-108	1
941	Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial. 2016 , 77, e1218-e1225	7
940	Are antidepressants and psychotherapy equally effective in treating depression? A critical commentary. 2016 , 25, 475-478	6
939	An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. 2016 , 31, 134-46	13

938	Catecholamine pathway polymorphisms and antidepressant response. 2016 , 8, 109-17	3
937	The psychometric properties of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) and the Patient Health Questionnaire-9 (PHQ-9) in depressed inpatients in China. 2016 , 243, 92-6	21
936	Ineffectiveness of nicotinic acetylcholine receptor antagonists for treatment-resistant depression: a meta-analysis. 2016 , 31, 241-8	5
935	Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. 2016 , 22, 1509-22	22
934	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre study. 2016 , 31, 1-7	16
933	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. 2016 , 46, 623-35	80
932	Clinimetric Dilemmas in Outcome Scales for Mental Disorders. 2016 , 85, 323-326	35
931	Conditional Beliefs of Primary-Care Patients with Treatment-Resistant Depression. 2016 , 44, 513-26	
930	[Antidepressant and tolerance: Determinants and management of major side effects]. 2016 , 42, 553-561	27
929	The relationship between calcitonin gene-related peptide and depression-like behavior. 2016 , 148, 139-43	
928	The Relationship Between Cortical Inhibition and Electroconvulsive Therapy in the Treatment of Major Depressive Disorder. 2016 , 6, 37461	9
927	Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. 2016 , 113, E8472-E8481	34
926	ABCB1 genotyping in the treatment of depression. 2016 , 17, 2039-2069	24
925	A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. 2016 , 26, 979-93	84
924	Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression. 2016 , 1647, 94-104	11
923	Hippocampal volume predicts antidepressant efficacy in depressed patients without incomplete hippocampal inversion. 2016 , 12, 949-955	13
922	Attenuation of oxidative and nitrosative stress in cortical area associates with antidepressant-like effects of tropisetron in male mice following social isolation stress. 2016 , 124, 150-63	36
921	Contemporary Treatment Approaches to Major Depression and Bipolar Disorders. 2016 , 51, 335-51	4

920	Female Flinders Sensitive Line rats show estrous cycle-independent depression-like behavior and altered tryptophan metabolism. 2016 , 329, 337-48	22
919	Chronic venlafaxine treatment fails to alter the levels of galanin system transcripts in normal rats. 2016 , 57, 65-70	11
918	Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. 2016 , 80, 424-431	225
917	What we know, what we do not know, and where are we heading? Efficacy and acceptability of psychological interventions for depression. 2016 , 25, 301-8	8
916	Influence of Exercise Intensity for Improving Depressed Mood in Depression: A Dose-Response Study. 2016 , 47, 527-37	59
915	The rapid antidepressant and anxiolytic-like effects of YY-21 involve enhancement of excitatory synaptic transmission via activation of mTOR signaling in the mPFC. 2016 , 26, 1087-98	10
914	Instant and Persistent Antidepressant Response of Gardenia Yellow Pigment Is Associated with Acute Protein Synthesis and Delayed Upregulation of BDNF Expression in the Hippocampus. 2016 , 7, 1068-76	22
913	Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. 2016 , 19, 769-78	7
912	Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. 2016 , 22, 238-49	732
911	Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014. 2016 , 26, 1-47	
910	Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders. 2016 , 70, 134-47	4
909	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. 2016 , 78, 11-23	153
908	Effect of Electroconvulsive Therapy on Striatal Morphometry in Major Depressive Disorder. 2016 , 41, 2481-91	59
907	Financial difficulties but not other types of recent negative life events show strong interactions with 5-HTTLPR genotype in the development of depressive symptoms. 2016 , 6, e798	13
906	Major Depressive Disorder. 2016 , 79-90	2
905	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. 2016 , 533, 481-6	903
904	Pharmacogenomics. 2016 , 121-135	
903	Antidepressants. 2016 , 205-245	

902 Recurrent Major Depressive Disorder of a Young Woman. **2016**, 14, 210-213

901 The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. *American Journal of Psychiatry*, **2016**, 173, 807-15 11.9 51

900 African-American representation in family and twin studies of mood and anxiety disorders: A systematic review. **2016**, 205, 311-318 2

899 The Need for Quality Improvement in Behavioral Health. **2016**, 33-54 2

898 Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. **2016**, 206, 151-160 12

897 Person-centered measurement-based care for depression. **2016**, 15, 238-239 5

896 Development of Antidepressant Drugs Through Targeting $\alpha 7$ -Nicotinic Acetylcholine Receptors. **2016**, 207-225

895 Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report. **2016**, 206, 232-240 15

894 Psychobiology of the intersection and divergence of depression and anxiety. **2016**, 33, 891-894 4

893 Right patient, right treatment, right time: biosignatures and precision medicine in depression. **2016**, 15, 237-238 12

892 Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial. **2016**, 26, 1768-1774 25

891 Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. **2016**, 37, 933-944 82

890 Using Electroencephalography for Treatment Guidance in Major Depressive Disorder. **2016**, 1, 411-422 30

889 Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment. **2016**, 58, 261-271 58

888 High occupational level is associated with poor response to treatment of depression. **2016**, 26, 1320-6 7

887 Comparative Effectiveness of Cognitive Therapy and Dynamic Psychotherapy for Major Depressive Disorder in a Community Mental Health Setting: A Randomized Clinical Noninferiority Trial. **2016**, 73, 904-11 58

886 Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. **2016**, 61, 540-60 469

885 Persistent post-stroke depression in mice following unilateral medial prefrontal cortical stroke. **2016**, 6, e863 47

884	Stem Cells in Neuroendocrinology. 2016 ,	1
883	Advances in Stem Cells Biology: New Approaches to Understand Depression. 2016 , 123-133	3
882	PPAR γ modulation of mesolimbic dopamine transmission rescues depression-related behaviors. 2016 , 110, 251-259	36
881	Improving Health Outcomes for Patients with Depression: A Population Health Imperative. Report on an Expert Panel Meeting. 2016 , 19 Suppl 2, S1-S12	8
880	Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. 2016 , 111, 242-252	99
879	Combining Psychodynamic Psychotherapy and Pharmacotherapy. 2016 , 44, 183-209	3
878	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. 2016 , 206, 17-22	16
877	Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray. 2016 , 113, E4726-35	31
876	Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?. 2017 , 31, 303-319	22
875	Subchronical treatment with Fluoxetine modifies the activity of the MCHergic and hypocretinergic systems. Evidences from peptide CSF concentration and gene expression. 2016 , 9, 89-93	2
874	Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. 2016 , 31, 412-418	22
873	Combination Strategies in Treatment-Resistant Depression. 2016 , 421-444	1
872	Targeting Opioid Receptors for Innovative Antidepressant Therapies: Rediscovering the Opioid Cure. 2016 , 631-653	
871	PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine. 2016 , 6, 26331	65
870	Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression. 2016 , 18, 563-570	10
869	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study. 2016 , 26, 1960-1971	33
868	Antidepressant-like effects of Xiaochaihutang in a neuroendocrine mouse model of anxiety/depression. 2016 , 194, 674-683	19
867	Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies. 2016 , 30, 1169-1189	12

866	Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression. 2016 , 7, 1635-1640	4
865	Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. 2017 , 20, 22-30	11
864	A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting. 2016 , 181, 1195-1199	37
863	Office care of breast disorders. 367-379	
862	Office management of depression. 394-404	
861	A training programme involving automatic self-transcending meditation in late-life depression: preliminary analysis of an ongoing randomised controlled trial. 2016 , 2, 195-198	9
860	The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol. 2016 , 16, 240	16
859	Using a smartphone app to reduce cognitive vulnerability and mild depressive symptoms: Study protocol of an exploratory randomized controlled trial. 2016 , 17, 609	6
858	Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. 2016 , 10, 236-43	10
857	Improving Depression Among HIV-Infected Adults: Transporting the Effect of a Depression Treatment Intervention to Routine Care. 2016 , 73, 482-488	17
856	Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine. 2016 , 31, 178-84	22
855	Exercise as a treatment for depression: A meta-analysis. 2016 , 202, 67-86	352
854	Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial. 2016 , 73, 685-94	165
853	iTRAQ technology-based identification of human peripheral serum proteins associated with depression. 2016 , 330, 291-325	32
852	Effects of the Synthetic Neurosteroid: 3 β -Methoxyprogesterone (MAP4343) on Behavioral and Physiological Alterations Provoked by Chronic Psychosocial Stress in Tree Shrews. 2016 , 19,	11
851	Progress and prospects in pharmacogenetics of antidepressant drugs. 2016 , 12, 1157-68	22
850	Evidence-Based Selection and Use of Antidepressants in Psychiatric Practice. 2016 , 46, 659-664	
849	Quality Improvement in Behavioral Health. 2016 ,	1

848	The FDA's failure to address the lack of generalisability of antidepressant efficacy trials in product labelling. 2016 , 208, 512-4	5
847	Stringent an Skalen orientierte Behandlung ist der Standardtherapie Berlegen. 2016 , 18, 16-17	0
846	Ovarian hormones, but not fluoxetine, impart resilience within a chronic unpredictable stress model in middle-aged female rats. 2016 , 107, 278-293	42
845	Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials. 2016 , 196, 171-80	8
844	Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain. 2016 , 9, 87-96	
843	Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models. 2016 , 17, 1029-40	3
842	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. 2016 , 16, 106	19
841	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. 2016 , 17, 66	9
840	Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression. 2016 , 79, 282-92	183
839	Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. 2016 , 233, 1679-88	53
838	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. 2016 , 3, 117-27	25
837	Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. 2016 , 233, 1235-43	38
836	Cross-trial prediction of treatment outcome in depression: a machine learning approach. 2016 , 3, 243-50	310
835	Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder. 2016 , 80, 439-447	44
834	Interpersonal psychotherapy as add-on for treatment-resistant depression: A pragmatic randomized controlled trial. 2016 , 193, 373-80	21
833	Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. 2016 , 16, 629-638	9
832	A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. 2016 , 21, 1372-80	24
831	Applying a free-water correction to diffusion imaging data uncovers stress-related neural pathology in depression. 2016 , 10, 336-42	37

830	Serotonin stimulates lateral habenula via activation of the post-synaptic serotonin 2/3 receptors and transient receptor potential channels. 2016 , 101, 449-59	28
829	Acute selective serotonin reuptake inhibitors regulate the dorsal raphe nucleus causing amplification of terminal serotonin release. 2016 , 136, 1131-1141	20
828	Transcriptomics and the mechanisms of antidepressant efficacy. 2016 , 26, 105-112	15
827	Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study. 2016 , 196, 11-9	17
826	Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor- β interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. 2016 , 144, 7-12	32
825	Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. 2016 , 21, 454-64	172
824	Antidepressant treatment response: 'I want it all, and I want it now!' 2016 , 208, 101-3	9
823	Practical guidance for prescribing trazodone extended-release in major depression. 2016 , 17, 433-41	5
822	Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. 2016 , 66, 31-8	12
821	Dose Response for SSRIs. <i>American Journal of Psychiatry</i> , 2016 , 173, 105-6	11.9 4
820	Electroconvulsive therapy increases temporal gray matter volume and cortical thickness. 2016 , 26, 506-17	67
819	SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept. 2016 , 41, 2324-34	18
818	TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. 2016 , 21, 1717-1725	71
817	Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. 2016 , 6, 99-144	78
816	Molecular biomarkers of depression. 2016 , 64, 101-33	62
815	Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. 2016 , 6, e741	51
814	A hospital for the mentally ill in the Middle Ages--psychiatry in history. 2016 , 208, 103	2
813	[Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain]. 2016 , 9, 87-96	2

812	[How to treat and manage unsatisfactory response?]. 2016 , 42, 1S39-47	1
811	[Roadmap for therapeutic strategies of treatment resistant depression]. 2016 , 45, 320-2	1
810	5HT3 receptors: Target for new antidepressant drugs. 2016 , 64, 311-25	27
809	Psychiatrists' Attitudes Toward Non-Pharmacologic Factors Within the Context of Antidepressant Pharmacotherapy. 2016 , 40, 783-9	5
808	Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice. 2016 , 301, 55-62	47
807	The protective effect of Hypericum connatum on stress-induced escape deficit in rat is related to its flavonoid content. 2016 , 54, 1782-92	11
806	Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. 2016 , 25, 464-72	7
805	Microglial dysfunction connects depression and Alzheimer's disease. 2016 , 55, 151-165	65
804	Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. 2016 , 17, 165-70	14
803	[Vortioxetine: a new antidepressant to treat depressive episodes]. 2016 , 42, 48-58	1
802	Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. 2016 , 190, 357-361	4
801	[Sequential prescriptions: Arguments for a change of therapeutic patterns in treatment resistant depressions]. 2016 , 42, 32-8	
800	Structural connectivity and response to ketamine therapy in major depression: A preliminary study. 2016 , 190, 836-841	30
799	BDNF - a key transducer of antidepressant effects. 2016 , 102, 72-9	460
798	Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). 2016 , 101, 46-56	8
797	The relationship between insomnia and major depressive disorder: a chicken and egg situation?. 2017 , 1	2
796	Vascular endothelial growth factor: Potential predictor of treatment response in major depression. 2017 , 18, 575-585	18
795	New targets for rapid antidepressant action. 2017 , 152, 21-37	92

794	Ketamine, depression et suicide : vers une nouvelle classe d'antidépresseurs ?. 2017 , 175, 121-126	
793	Monoacylglycerol lipase inhibitors produce pro- or antidepressant responses via hippocampal CA1 GABAergic synapses. 2017 , 22, 215-226	31
792	Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. 2017 , 22, 552-561	98
791	Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. 2017 , 112, 210-220	50
790	Intrinsic functional connectivity in late-life depression: trajectories over the course of pharmacotherapy in remitters and non-remitters. 2017 , 22, 450-457	40
789	Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. 2017 , 18, 39-53	32
788	Distinct Neural-Functional Effects of Treatments With Selective Serotonin Reuptake Inhibitors, Electroconvulsive Therapy, and Transcranial Magnetic Stimulation and Their Relations to Regional Brain Function in Major Depression: A Meta-analysis. 2017 , 2, 318-326	8
787	Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression: A systematic review and meta-analysis of randomized controlled clinical trials. 2017 , 211, 65-74	57
786	Measures of the DSM-5 mixed-features specifier of major depressive disorder. 2017 , 22, 196-202	6
785	Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats. 2017 , 7, e1038	40
784	Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective μ opioid receptor antagonists. 2017 , 130, 15-25	15
783	Restoring function in major depressive disorder: A systematic review. 2017 , 215, 299-313	68
782	A prognostic index (PI) as a moderator of outcomes in the treatment of depression: A proof of concept combining multiple variables to inform risk-stratified stepped care models. 2017 , 213, 78-85	32
781	Effect of XingPiJieYu decoction on spatial learning and memory and cAMP-PKA-CREB-BDNF pathway in rat model of depression through chronic unpredictable stress. 2017 , 17, 73	39
780	Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. 2017 , 74, 370-378	135
779	Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study. 2017 , 6, 22-30	17
778	Pharmacogenetics of antidepressant response: A polygenic approach. 2017 , 75, 128-134	54
777	No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patients. 2017 , 18, 349-357	0

776	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. 2017 , 267, 723-735	14
775	Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. 2017 , 77, 381-401	69
774	The multiple diagnoses of comorbid anxiety disorders and higher interpersonal sensitivity predict treatment-resistant depression. 2017 , 26, 131-135	5
773	Alpha Wavelet Power as a Biomarker of Antidepressant Treatment Response in Bipolar Depression. 2017 , 968, 79-94	4
772	Novel 5-HT _{2A} antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile. 2017 , 25, 2789-2799	14
771	Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. 2017 , 140, 472-486	44
770	The Comparison of Effectiveness of Various Potential Predictors of Response to Treatment With SSRIs in Patients With Depressive Disorder. 2017 , 205, 618-626	9
769	Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms. 2017 , 1, 1-10	41
768	Suppression of reward-induced dopamine release in the nucleus accumbens in animal models of depression: Differential responses to drug treatment. 2017 , 650, 72-76	16
767	Antidepressant-like activity of icariin mediated by group I mGluRs in prenatally stressed offspring. 2017 , 39, 593-600	12
766	Resolvin D1 and D2 Reverse Lipopolysaccharide-Induced Depression-Like Behaviors Through the mTORC1 Signaling Pathway. 2017 , 20, 575-584	48
765	Antidepressant-like effect of valproic acid-Possible involvement of PI3K/Akt/mTOR pathway. 2017 , 329, 166-171	20
764	Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response. 2017 , 33, 117-121	6
763	Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression I: bio-behavioural validation and response to imipramine. 2017 , 29, 193-206	12
762	Classics in Chemical Neuroscience: Ketamine. 2017 , 8, 1122-1134	57
761	Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?. 2017 , 18, 639-650	15
760	Effects of chronic bryostatin-1 on treatment-resistant depression in rats. 2017 , 807, 71-74	5
759	Phf8 loss confers resistance to depression-like and anxiety-like behaviors in mice. 2017 , 8, 15142	23

758	Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. 2017 , 234, 1649-1661	40
757	Factors associated with response after deep transcranial magnetic stimulation in a real-world clinical setting: Results from the first 40 cases of treatment-resistant depression. 2017 , 44, 61-67	6
756	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. 2017 , 218, 277-283	30
755	Aldosterone concentrations in saliva reflect the duration and severity of depressive episode in a sex dependent manner. 2017 , 91, 164-168	24
754	The impact of the halogen bonding on D and 5-HT/5-HT receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. 2017 , 25, 3638-3648	16
753	Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. 2017 , 234, 2453-2461	33
752	Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model. 2017 , 332, 233-236	26
751	Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data. 2021 , 46, 1293-1299	2
750	No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients. 2021 , 44, 53-56	
749	Yoga for Mental Health Disorders. 2021 , 179-198	1
748	"Novel Psychopharmacology for Depressive Disorders". 2021 , 1305, 449-461	8
747	Genetic and Environmental Contributions to Mental Illness With Implications for Evaluation and Treatment. 2021 , 59, 9-13	
746	Psychopharmacology Algorithms for Major Depressive Disorder: Current Status. 2021 , 1305, 429-445	
745	Sortilin/neurotensin receptor-3 and its derived peptides in depression. 2021 , 235-241	
744	Antidepressant Drugs. 2021 ,	
743	A Web-Based Group Cognitive Behavioral Therapy Intervention for Symptoms of Anxiety and Depression Among University Students: Open-Label, Pragmatic Trial (Preprint).	
742	Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. 2021 , 35, 142-149	6
741	Memantine in neurological disorders - schizophrenia and depression. 2021 , 99, 327-334	5

740	Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. 2021 , 14, 1359-1368	4
739	Examining sex differences in neurodevelopmental and psychiatric genetic risk in anxiety and depression.	
738	SIRT1 and SIRT2 Modulators: Potential Anti-Inflammatory Treatment for Depression?. 2021 , 11,	2
737	Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome. 2021 , 92, 1069-1077	
736	Advances in digital psychiatry: Towards an extended definition of major depressive disorder symptomatology (Preprint).	1
735	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. 2021 , 11, 127	5
734	Shaping therapeutic trajectories in mental health: Instructive vs. permissive causality. 2021 , 43, 1-9	8
733	Selective ablation of type 3 adenylyl cyclase in somatostatin-positive interneurons produces anxiety- and depression-like behaviors in mice. 2021 , 11, 21-35	
732	Toward an Extended Definition of Major Depressive Disorder Symptomatology: Digital Assessment and Cross-validation Study. 2021 , 5, e27908	0
731	Selective ablation of type 3 adenylyl cyclase in somatostatin-positive interneurons produces anxiety- and depression-like behaviors in mice. 2021 , 11, 35-49	0
730	Why Is Exercise Underutilized in Clinical Practice Despite Evidence It Is Effective? Lessons in Pragmatism From the Inclusion of Exercise in Guidelines for the Treatment of Depression in the British National Health Service. 2021 , 10, 29-50	1
729	From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?. 2021 , 12, 638032	3
728	Selective serotonin reuptake inhibitor treatment retunes emotional valence in primate ventral striatum. 2021 , 46, 2073-2082	2
727	A surrogate measure for patient reported symptom remission in administrative data. 2021 , 21, 121	2
726	Photobiomodulation Therapy Ameliorates Glutamatergic Dysfunction in Mice with Chronic Unpredictable Mild Stress-Induced Depression. 2021 , 2021, 6678276	3
725	Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. 2021 , 282, 1272-1277	0
724	Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study. 2021 , 44, 23-33	4
723	Desvenlafaxine in the treatment of major depression: an updated overview. 2021 , 22, 1087-1097	0

722	Depression. 2021 , 128-138	
721	Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India. 2021 , 57,	
720	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. 2021 , 26, 3363-3373	20
719	Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. 2021 , 26, 232-242	1
718	Vasopressin V1B Receptor Antagonists as Potential Antidepressants. 2021 , 24, 450-463	3
717	P.229 Targeting neural plasticity in adolescent depressed-like mice to promote treatment efficacy. 2021 , 44, S35-S36	
716	Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response. 2021 , 11, 201	1
715	Potential clinical value of circular RNAs as peripheral biomarkers for the diagnosis and treatment of major depressive disorder. 2021 , 66, 103337	13
714	Addressing adherence to antidepressant treatment for depression. 2021 , 43, 125-126	
713	Xiaoyaosan Alleviates Hippocampal Glutamate-Induced Toxicity in the CUMS Rats via NR2B and PI3K/Akt Signaling Pathway. 2021 , 12, 586788	5
712	Making a case for the inclusion of refractory and severe mental illness as a sole criterion for Canadians requesting medical assistance in dying (MAiD): a review. 2021 ,	0
711	Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. 2021 , 285, 112-119	4
710	Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials. 2021 , 1-9	4
709	Increasing Adult Hippocampal Neurogenesis Promotes Resilience in a Mouse Model of Depression. 2021 , 10,	4
708	Machine Learning-Based Personalized Pharmacological Treatment for Depressive Disorder: A Target Trial Emulation Study (Preprint).	
707	The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder. 2021 , 39, 691-706	1
706	Escitalopram Administration, Neuroplastic Effects and Relearning: A Diffusion Tensor Imaging Study in Healthy Individuals.	
705	Perceived helpfulness of depression treatments among young adults with autism. 2021 , 14, 1522-1528	0

704	Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. 2021 , 11, 249	5
703	Stress Resilience is Associated with Hippocampal Synaptoprotection in the Female Rat Learned Helplessness Paradigm. 2021 , 459, 85-103	2
702	Repetitive transcranial magnetic stimulation in major depression: A three-arm parallel-group dose-response randomized pilot trial. 2021 , 100, e25273	
701	Trial of Psilocybin versus Escitalopram for Depression. 2021 , 384, 1402-1411	152
700	Do different types of stress differentially alter behavioural and neurobiological outcomes associated with depression in rodent models? A systematic review. 2021 , 61, 100896	5
699	Brain-immune crosstalk in the treatment of major depressive disorder. 2021 , 45, 89-107	19
698	Prevalence and risk factors of overweight and obesity in Chinese patients with first-episode drug-naïve major depressive disorder. 2021 , 286, 351-359	1
697	Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer's Disease and Depression. 2021 , 28, 2328-2345	6
696	Scientific Advances Supporting New and Improved Treatment Strategies in Psychiatry. <i>American Journal of Psychiatry</i> , 2021 , 178, 365-368	11.9
695	5-HTTLPR-rs25531 and Antidepressant Treatment Outcomes in Korean Patients with Major Depression. 2021 , 54, 269-278	0
694	Research on the Tufts Be Well at Work Program for Employees With Depression: 2005-2020. 2021 , 72, 1441-1450	0
693	The GABA(B1) receptor within the infralimbic cortex is implicated in stress resilience and vulnerability in mice. 2021 , 406, 113240	1
692	Glycine/NMDA Receptor Pathway Mediates the Rapid-onset Antidepressant Effect of Alkaloids From .. 2021 , 12, 395-408	0
691	Setting Measurement-Based Care in Motion: Practical Lessons in the Implementation and Integration of Measurement-Based Care in Psychiatry Clinical Practice. 2021 , 17, 1621-1631	3
690	Economic burden of treatment-resistant depression among veterans in the United States. 2021 , 37, 1393-1401	0
689	Machine learning to predict clinical remission in depressed patients after acute phase selective serotonin reuptake inhibitor treatment. 2021 , 287, 372-379	1
688	Specific sub-regions along the longitudinal axis of the hippocampus mediate antidepressant-like behavioral effects. 2021 , 14, 100331	4
687	A Web-Based Group Cognitive Behavioral Therapy Intervention for Symptoms of Anxiety and Depression Among University Students: Open-Label, Pragmatic Trial. 2021 , 8, e27400	3

686	A Scientometrics Analysis and Visualization of Depressive Disorder. 2021 , 19, 766-786	2
685	The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. 2021 , 54, 191-199	6
684	Pharmacists as facilitators of pharmacogenomic guidance for antidepressant drug selection and dosing. 2021 , 14, 1206-1209	0
683	Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. 2021 , 19, 243-253	1
682	Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study. 2021 , 46, E358-E368	4
681	Activation of liver X receptors prevents emotional and cognitive dysfunction by suppressing microglial M1-polarization and restoring synaptic plasticity in the hippocampus of mice. 2021 , 94, 111-124	9
680	Involvement of Scratch2 in GalR1-mediated depression-like behaviors in the rat ventral periaqueductal gray. 2021 , 118,	1
679	Validation of the Multidimensional Assessment of Interoceptive Awareness (MAIA-2) questionnaire in hospitalized patients with major depressive disorder. 2021 , 16, e0253913	2
678	The Association of Current Tobacco Status With Pain and Symptom Severity in Fibromyalgia Patients. 2021 , 5, 614-624	
677	Adjunctive Nonconvulsive Electrotherapy for Patients with Depression: a Systematic Review. 2021 , 92, 1645-1656	2
676	Personalized machine learning of depressed mood using wearables. 2021 , 11, 338	3
675	The Patient Mania Questionnaire (PMQ-9): a Brief Scale for Assessing and Monitoring Manic Symptoms. 2021 , 1	2
674	Selecting antidepressants according to a drug-by-environment interaction: A comparison of fluoxetine and minocycline effects in mice living either in enriched or stressful conditions. 2021 , 408, 113256	2
673	A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder. 2021 , 12, 689143	0
672	Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness. 2021 , 19, 39-45	1
671	P2RX7 gene variation mediates the effect of childhood adversity and recent stress on the severity of depressive symptoms. 2021 , 16, e0252766	1
670	Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram. 2021 , 31, 172-176	0
669	Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. 2021 , 11, 381	7

668	Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report. 2021 , 17, 2333-2345	3
667	Allopregnanolone in mood disorders: Mechanism and therapeutic development. 2021 , 169, 105682	5
666	The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness. 2021 , 12, 680626	1
665	The Role of Board-Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes. 2021 , 72, 794-801	3
664	Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. 2021 , 129, 105234	2
663	Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine. 2021 , 15, 698633	3
662	Perspectives for therapy of treatment-resistant depression. 2021 ,	5
661	Transcranial Magnetic Stimulation Indices of Cortical Excitability Enhance the Prediction of Response to Pharmacotherapy in Late-Life Depression. 2021 ,	0
660	Resolvin D2 attenuates chronic pain-induced depression-like behavior in mice. 2021 , 41, 426-429	1
659	Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review. 2021 , 17, 2397-2419	1
658	Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk?. 2021 , 290, 254-260	0
657	Epigenetics: A missing link between early life stress and depression. 2021 , 109, 110231	8
656	Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report. 2021 , 11,	1
655	Guidelines improve patient outcomes in specialised mental health care: A systematic review and meta-analysis. 2021 , 144, 246-258	2
654	Effects of transcranial magnetic stimulation on anhedonia in treatment resistant major depressive disorder. 2021 , 11, e2329	4
653	Synthesized difference in differences. 2021 ,	
652	Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?. 2021 ,	2
651	An acute dose-ranging evaluation of the antidepressant properties of Scelletium tortuosum (Zembrin®) versus escitalopram in the Flinders Sensitive Line rat. 2022 , 284, 114550	0

650	Transthyretin as a Biomarker to Predict and Monitor Major Depressive Disorder Identified by Whole-Genome Transcriptomic Analysis in Mouse Models. 2021 , 9,	1
649	The prefrontal cortex, pathological anxiety, and anxiety disorders. 2022 , 47, 260-275	8
648	Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression. 2021 , 207, 173226	3
647	Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine : Utiliser l'apprentissage machine pour prédire la rémission chez les patients souffrant de trouble dépressif majeur traité par desvenlafaxine. 2021 , 7067437211037141	
646	A narrative review on invasive brain stimulation for treatment-resistant depression. 2021 ,	1
645	Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. 2021 , 11, 417	4
644	Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders. 2021 , 19, 490-497	1
643	Intrinsic Functional Connectomes Characterize Neuroticism in Major Depressive Disorder and Predict Antidepressant Treatment Outcomes. 2021 , 7, 276-276	1
642	Antidepressant-like Effect of 3-n-Butylphthalide in Rats Exposed to Chronic Unpredictable Mild Stress: Modulation of Brain-Derived Neurotrophic Factor Level and mTOR Activation in Cortex. 2021 , 46, 3075-3084	2
641	Identifying the Common Genetic Basis of Antidepressant Response. 2021 ,	4
640	Physiological markers of rapid antidepressant effects of allopregnanolone. 2021 , e13023	0
639	Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges. 2021 , 90, 236-242	5
638	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. 2021 , 11,	2
637	Accounting for symptom heterogeneity can improve neuroimaging models of antidepressant response after electroconvulsive therapy. 2021 , 42, 5322-5333	4
636	Every Night and Every Morn: Effect of Variation in Gene on Depression Depends on Exposure to Early and Recent Stress. 2021 , 12, 687487	1
635	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. 2021 , 292, 714-719	4
634	The impact of a single session of aerobic exercise on positive emotional reactivity in depression: Insight into individual differences from the late positive potential. 2021 , 144, 103914	1
633	The effect of selective serotonin reuptake inhibitors on cognitive impairment in patients with depression: A prospective, multicenter, observational study. 2021 , 141, 26-33	1

632	Molecular mechanism of Epicedium treatment for depression based on network pharmacology and molecular docking technology. 2021 , 21, 222	3
631	Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: A cross-sectional study. 2022 , 296, 476-484	1
630	Patient, family and provider views of measurement-based care in an early-psychosis intervention programme. 2021 , 7,	1
629	Significant reduction in depressive symptoms among patients with moderately-severe to severe depressive symptoms after participation in a therapist-supported, evidence-based mobile health program delivered via a smartphone app. 2021 , 25, 100408	0
628	Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders. 2021 , 196, 108687	4
627	A Multiscale View of the Mechanisms Underlying Ketamine's Antidepressant Effects: An Update on Neuronal Calcium Signaling. 2021 , 15, 749180	3
626	Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings. 2021 , 75, 341-350	0
625	Examining sex differences in neurodevelopmental and psychiatric genetic risk in anxiety and depression. 2021 , 16, e0248254	2
624	Folate as adjunct therapy to SSRI/SNRI for major depressive disorder: Systematic review & meta-analysis. 2021 , 61, 102770	2
623	Heterogeneity in major depression and its melancholic and atypical specifiers: a secondary analysis of STAR*D. 2021 , 21, 454	0
622	Altered effective connectivity in sensorimotor cortices is a signature of severity and clinical course in depression. 2021 , 118,	3
621	Baseline beliefs about medication are associated with outcomes of antidepressants in inpatients with first-diagnosed depression under supervised therapeutic compliance. 2021 , 13, 21400-21407	0
620	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. 2022 , 296, 485-492	
619	A Roadmap for Measurement-based Care Implementation in Intensive Outpatient Treatment Settings for Children and Adolescents. 1-20	
618	Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine. 2021 , 7, eabi6856	3
617	Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. 2021 , 78, 951-959	14
616	A Role of BDNF in the Depression Pathogenesis and a Potential Target as Antidepressant: The Modulator of Stress Sensitivity "Shati/Nat8l-BDNF System" in the Dorsal Striatum. 2021 , 14,	4
615	Synergistic effects of resilience and serum ghrelin levels on the 12-week pharmacotherapeutic response in patients with depressive disorders. 2021 , 295, 1489-1493	0

614	Resolvins as potential candidates for the treatment of major depressive disorder. 2021 , 147, 33-39	1
613	Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?. 2021 , 27, 361-371	3
612	From serendipity to rational drug design in brain disorders: in silico, in vitro, and in vivo approaches. 2021 , 60, 177-182	0
611	Resolvin E1 Attenuates Chronic Pain-Induced Depression-Like Behavior in Mice: Possible Involvement of Chemerin Receptor ChemR23. 2021 , 44, 1548-1550	0
610	Effects of various statins on depressive symptoms: A network meta-analysis. 2021 , 293, 205-213	6
609	Beyond the neuro-immune interplay in depression: Could gut microbes be the missing link?. 2021 , 16, 100308	1
608	Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. 2021 , 16, 100313	1
607	A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). 2021 , 37, 2163-2173	4
606	The Resilient Phenotype Induced by Prophylactic Ketamine Exposure During Adolescence Is Mediated by the Ventral Tegmental Area-Nucleus Accumbens Pathway. 2021 , 90, 482-493	4
605	Transdiagnostic biomarker approaches to mental health disorders: Consideration of symptom complexity, comorbidity and context. 2021 , 16, 100303	3
604	Inflammatory cytokines, cognition, and response to antidepressant treatment in patients with major depressive disorder. 2021 , 305, 114202	1
603	Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. 2021 , 227, 107873	3
602	Antidepressant treatment outcomes in patients with and without comorbid physical or psychiatric disorders: A systematic review and meta-analysis. 2021 , 295, 225-234	1
601	Quercetin reverses chronic unpredictable mild stress-induced depression-like behavior in vivo by involving nuclear factor-E2-related factor 2. 2021 , 1772, 147661	8
600	Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study. 2022 , 112, 110425	5
599	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. 2021 , 46, 1272-1282	4
598	Dentate gyrus activin signaling mediates the antidepressant response. 2021 , 11, 7	4
597	Immunoregulation and antidepressant effect of ketamine. 2021 , 12, 218-236	4

596	Psychometric approach in psychiatry: excess or necessity?. 2020 , LII, 9-14	
595	Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury. 2021 , 44, 102-162	1
594	Exercise and the Brain. 2011 , 257-273	2
593	Pharmacogenomics Applications in Psychiatric Disorders. 2008 , 369-394	1
592	Physical activity, stress reduction, and mood: insight into immunological mechanisms. 2012 , 934, 89-102	44
591	Predicting Response to the Antidepressant Bupropion using Pretreatment fMRI. 2019 , 11843, 53-62	7
590	Classification Systems of Mental Disorders: Where Did We Go Wrong?. 2020 , 193-203	0
589	The Change of Resting EEG in Depressive Disorders. 2013 , 52-61	4
588	Basic Study Design. 2015 , 89-121	3
587	Targeting the GABAB Receptor for the Treatment of Depression and Anxiety Disorders. 2016 , 219-250	5
586	Psychopharmaka. 2007 , 819-868	4
585	Psychopharmaka. 2008 , 773-817	3
584	Psychopharmaka. 2008 , 775-819	1
583	Psychopharmaka. 2010 , 797-842	3
582	Antidepressiva. 2012 , 589-628	0
581	Psychopharmaka. 2011 , 813-858	1
580	Encyclopedia of Psychopharmacology. 2013 , 1-5	1
579	Psychopharmaka. 2012 , 833-879	1

578	P2X7 in Bipolar and Depressive Disorders. 2014 , 635-661	2
577	The Role of Gut Microbiota in the Antidepressant Effects of Ketamine. 2020 , 127-141	2
576	Introduction. 2019 , 1180, 1-17	3
575	Optimized Treatment Strategy for Depressive Disorder. 2019 , 1180, 201-217	4
574	Internet-Based Management for Depressive Disorder. 2019 , 1180, 267-276	1
573	Ketamine: The final frontier or another depressing end?. 2020 , 383, 112508	14
572	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 ,	6
571	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 6-19	2
570	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 20-44	3
569	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 45-65	3
568	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 66-81	1
567	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 145-172	0
566	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 180-206	6
565	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 207-223	3
564	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 224-238	1
563	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 239-265	2
562	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 266-280	3
561	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 281-303	3

560	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 304-321	2
559	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 322-337	2
558	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 338-356	1
557	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 393-408	3
556	A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. 2017 , 409-430	1
555	Pre-treatment allostatic load and metabolic dysregulation predict SSRI response in major depressive disorder: a preliminary report. 2020 , 1-9	2
554	Follow-up of monotherapy remitters in the PRedICT study: Maintenance treatment outcomes and clinical predictors of recurrence. 2018 , 86, 189-199	9
553	Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. 2018 , 86, 282-293	29
552	Bioethics and the Brain. 2006 ,	13
551	Drugs Don't Talk: Do Medication and Biological Psychiatry Contribute to Silencing the Self?. 2010 , 47-72	5
550	Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. 2009 , 19, 67-76	39
549	Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample. 2009 , 19, 235-8	22
548	Initial Severity Effects on Residual Symptoms in Response and Remission: A STAR*D Study During and After Failed Citalopram Treatment. 2015 , 35, 450-3	14
547	The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine. 2011 , 28, 478-82	26
546	Towards an emotional stress test: a reliable, non-subjective cognitive measure of anxious responding.	1
545	Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug Classes.	1
544	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.	3
543	Genome-wide translating mRNA analysis following ketamine reveals novel targets for antidepressant treatment.	2

542	Differential Treatment Benefit Prediction For Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data.	2
541	Efficacy of chronic ultrasound neurostimulation on behaviors and distributed brain metabolism in depressive-like mice.	1
540	Effects of psilocybin therapy on personality structure. 2018 , 138, 368-378	85
539	Redefining Affective Disorders: Relevance for Drug Development. 2008 , 14, 2-9	31
538	Differential Treatment Benefit Prediction for Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data. 2020 , 4, 61	2
537	Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. 2019 , 129, 2542-2554	30
536	Improving Depression Outcome by Patient-Centered Medical Management. 2020 , 18, 244-254	1
535	Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 2009 , 60, 1446-57	41
534	Implementation of collaborative depression management at community-based primary care clinics: an evaluation. 2011 , 62, 1047-53	34
533	Depression and diabetes: factors associated with major depression at five-year follow-up. 2009 , 50, 570-9	46
532	[Resolvins as novel targets for rapid-acting antidepressants]. 2020 , 155, 381-385	2
531	Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?. 2018 , 24, 3136-3145	3
530	Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. 2008 , 3, e1872	129
529	Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. 2014 , 9, e83879	54
528	Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression. 2014 , 9, e93772	53
527	Genetic prediction of antidepressant drug response and nonresponse in Korean patients. 2014 , 9, e107098	14
526	The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development. 2016 , 11, e0152729	12
525	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. 2016 , 11, e0167901	18

524	A wavelet-based technique to predict treatment outcome for Major Depressive Disorder. 2017 , 12, e0171409	49
523	People with diabetes need a lower cut-off than others for depression screening with PHQ-9. 2020 , 15, e0240209	4
522	5-HT _{2A} Serotonin Receptor Density in Adult Male Rats' Hippocampus after Morphine-based Conditioned Place Preference. 2016 , 7, 249-58	3
521	[Multimodal serotonergic antidepressants]. 2017 , 117, 103-111	1
520	[Perspectives of the use of pharmacogenetic tests in neurology and psychiatry]. 2019 , 119, 131-135	1
519	Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients. 2016 , 7, 17415-30	18
518	White Paper: Efficacy of Psychiatric Drugs. 2016 , 18, 20-28	3
517	Transcriptional dys-regulation in anxiety and major depression: 5-HT _{1A} gene promoter architecture as a therapeutic opportunity. 2014 , 20, 3738-50	32
516	Vitamin D and N-Acetyl Cysteine Supplementation in Treatment-Resistant Depressive Disorder Patients: A General Review. 2020 , 26, 2442-2459	4
515	Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. 2013 , 14, 1225-36	357
514	Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response. 2020 , 18, 301-318	5
513	Web-Based Cognitive Behavioral Therapy Blended With Face-to-Face Sessions for Major Depression: Randomized Controlled Trial. 2018 , 20, e10743	13
512	Cost and Effectiveness of Blended Versus Standard Cognitive Behavioral Therapy for Outpatients With Depression in Routine Specialized Mental Health Care: Pilot Randomized Controlled Trial. 2019 , 21, e14261	28
511	e-CBT (myCompass), Antidepressant Medication, and Face-to-Face Psychological Treatment for Depression in Australia: A Cost-Effectiveness Comparison. 2015 , 17, e255	30
510	Smartphone Cognitive Behavioral Therapy as an Adjunct to Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. 2017 , 19, e373	65
509	Efficacy of different doses of ketamine as a bolus in major depressive disorder. 2018 , 9, 220-227	2
508	Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables. 2020 , 17, 193-206	11
507	Pharmacogenetics and Depression: A Critical Perspective. 2019 , 16, 645-653	9

506	Measurement-Based Care and Outcome Measures: Implications for Practice. 2009 , 127-137	1
505	Treatments in depression. 2006 , 8, 191-206	19
504	Incomplete remission in depression: role of psychiatric and somatic comorbidity. 2008 , 10, 453-60	25
503	Psychosocial determinants of recovery in depression. 2008 , 10, 461-72	8
502	Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. 2008 , 10, 439-51	70
501	Treatment strategies to improve and sustain remission in major depressive disorder. 2008 , 10, 377-84	52
500	A new paradigm for the prediction of antidepressant treatment response. 2009 , 11, 435-46	48
499	Psychiatric pharmacogenomic testing in clinical practice. 2010 , 12, 69-76	45
498	Effectiveness studies: advantages and disadvantages. 2011 , 13, 199-207	34
497	Brain rhythms and neural syntax: implications for efficient coding of cognitive content and neuropsychiatric disease. 2012 , 14, 345-67	295
496	Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. 2014 , 16, 11-27	160
495	Epigenetic alterations in depression and antidepressant treatment. 2014 , 16, 395-404	99
494	Pharmacological approaches to the challenge of treatment-resistant depression. 2015 , 17, 111-26	95
493	The Behavioral and Neurochemical Aspects of the Interaction between Antidepressants and Unpredictable Chronic Mild Stress. 2020 , 12, 63-72	5
492	Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antidepressants in Depression (ADD Study). 2015 , 2, 1-98	5
491	Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. 2018 , 22, 1-136	16
490	Depressive Symptoms in Schizophrenia Outpatients: Prevalence and Clinical Correlates. 2008 , 2, 127-135	9
489	Sensorimotor modulation of mood and depression: in search of an optimal mode of stimulation. 2013 , 7, 428	14

488	Graduate mental health worker case management of depression in UK primary care: a pilot study. 2007 , 57, 880-5	14
487	The ABCB1 transporter gene and antidepressant response. 2009 , 1, 23	9
486	Researches of the imidazole and indole derivatives cerebroprotective activity and its impact on effects of antidepressants. 2020 , 18-24	2
485	Clinically Relevant Findings from STAR*D. 2008 , 38,	11
484	The Role and Postulated Biochemical Mechanism of L-Methylfolate Augmentation in Major Depression: A Case-Report. 2014 , 44, 197-204	2
483	Vagus nerve stimulation for depression and other neuropsychiatric disorders. 2006 , 44, 11-4	2
482	Pharmacotherapy strategies for treatment-resistant depression. 2006 , 44, 11-4	1
481	Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design. 2008 , 46, 21-4	27
480	Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. 2008 , 46, 21-4	49
479	A critical evaluation of the cardiac toxicity of citalopram: part 2. 2011 , 49, 13-6	13
478	Improving Quality Outcomes in Veteran-Centric Care. 2017 , 55, 37-44	2
477	Engagement in Psychotherapy Improves Outcomes for Veterans. 2019 , 57, 30-38	2
476	Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?. 2012 , 73, 1439-42	6
475	Clinical predictors of ketamine response in treatment-resistant major depression. 2014 , 75, e417-23	100
474	Prognostic subgroups for citalopram response in the STAR*D trial. 2014 , 75, 738-47	50
473	Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. 2015 , 76, 189-94	16
472	Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study. 2020 , 81,	10
471	A computerized decision support system for depression in primary care. 2009 , 11, 140-6	32

470	"Caseness" for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories. 2009 , 11, 307-15	19
469	Clinical implications of genetic variation in the serotonin transporter promoter region: a review. 2009 , 11, 93-102	30
468	Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. 2010 , 12,	23
467	Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials. 2010 , 12,	9
466	The effectiveness of antidepressant monotherapy in a naturalistic outpatient setting. 2012 , 14,	4
465	A review of antidepressant therapy in primary care: current practices and future directions. 2013 , 15,	20
464	A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. 2015 , 17,	14
463	Tackling partial response to depression treatment. 2009 , 11, 155-62	2
462	Use of treatment algorithms for depression. 2006 , 8, 291-8	12
461	Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study. 2007 , 9, 271-9	4
460	Translating Science Into Service: Lessons Learned From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. 2007 , 9, 331-7	10
459	A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. 2008 , 10, 25-30	17
458	What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis. 2008 , 10, 91-6	51
457	Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. 2008 , 10, 440-7	33
456	A Patient Bill of Rights for Psychotropic Prescription: A Call for a Higher Standard of Care. 2011 , 02, 353-359	1
455	Paroxetine Increased the Serum Estrogen in Postmenopausal Women with Depressive and Anxiety Symptoms. 2014 , 03, 184-194	4
454	No effect of serotonergic gene variants on response to interpersonal counseling and antidepressants in major depression. 2013 , 10, 180-9	18
453	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. 2014 , 11, 371-9	9

452	Symptom-based selection of antidepressants. 2020 , 63, 216-226	1
451	A specific role for serotonin in overcoming effort cost. 2016 , 5,	45
450	Evaluation of QTc prolongation and dosage effect with citalopram. 2016 , 6, 165-170	2
449	Impact of a clinical pharmacist-managed clinic in primary care mental health integration at a Veterans Affairs health system. 2018 , 8, 105-109	11
448	Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?. 2018 , 8, 175-183	11
447	Key differences between Venlafaxine XR and Desvenlafaxine: An analysis of pharmacokinetic and clinical data. 2014 , 4, 35-39	8
446	A review of the evidence supporting the use of lithium augmentation therapy for the reduction of suicidal behavior in patients with unipolar depression: Revisiting an overlooked benefit of an older medication. 2014 , 4, 221-225	1
445	Pharmacogenomics of antidepressants for major depressive disorder. 2012 , 1, 222-224	1
444	Feasibility and acceptability of a Whole-Body hyperthermia (WBH) protocol. 2021 , 38, 1529-1535	
443	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis.. 2021 , 51, 2742-2751	3
442	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. 2021 , 11, 531	0
441	Plasma acetyl-l-carnitine and l-carnitine in major depressive episodes: a case-control study before and after treatment.. 2021 , 1-10	0
440	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. 2021 , 11, 513	2
439	Treatment Resistant Depression. 2021 , 13, 77-95	
438	Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. 2021 , 1	0
437	A Sobering Look at Treatment Effectiveness of Military-Related Posttraumatic Stress Disorder. 216770262110513	
436	Gender gap in health service utilisation and outcomes of depression: A cross-country longitudinal analysis of European middle-aged and older adults. 2021 , 153, 106847	1
435	An overview of the behavioral, neurobiological and morphological effects of topiramate in rats exposed to chronic unpredictable mild stress. 2021 , 912, 174578	0

434 Principles & practice of polypharmacotherapy. **2006**, 44, 13-6

1

433 SUPPORT FOR UNIVERSAL HEALTH CARE COVERAGE WILL ALLOW US TO PRACTICE ETHICAL MEDICINE. **2006**, 6, 4-5

432 Neuroimaging. **2006**, 45-75

431 Introduction. **2006**, 3-12

430 Brain, Body, and Self. **2006**, 13-44

429 Brain Death. **2006**, 148-178

428 Pharmacological and Psychological Interventions. **2006**, 76-115

427 Neurosurgery, Psychosurgery, and Neurostimulation. **2006**, 116-147

426 Epilogue. **2006**, 179-180

425 Therapeutic Neuromodulation: Clinical and Research Implications of a New Therapeutic Platform. **2007**, 37,

424 Electroconvulsive therapy--an outdated treatment, or one whose time has come?. **2007**, 100, 462-3

423 Translational Research in Psychiatric Diseases. **2007**, 195-210

422 Diagnosis and treatment of major depression 2007. **2007**, 11, 35-42

2

421 Principles of management. **2007**, 9-28

420 Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. **2008**, 971-983

419 Bipolar Disorder. **2008**, 399-414

1

418 Pharmacological Approaches to Treatment-Resistant Depression. **2008**, 621-634

417 Depressive Störungen. **2008**, 1401-1472

- 416 Pharmacogenetics of Major Depressive Disorder. **2008**, 38,
- 415 DRUG DEVELOPMENT. **2009**, 15-28
- 414 DEPRESSION AND BIPOLAR DISORDERS. **2009**, 787-795
- 413 Depression. **2009**, 1163-1167
- 412 Algorithms: STAR*D, Positives, Negatives, and Implications for Clinical Practice. **2009**, 117-126
- 411 Combining Medications to Achieve Remission. **2009**, 54-100 1
- 410 Outcomes in the Treatment of Major Depressive Disorder. **2009**, 22-53
- 409 Evidence-Based Medicine. **2010**, 229-243
- 408 Psychopharmacology Today: Where are We and Where Do We Go From Here?. **2010**, 8, 6-16 5
- 407 Antidepressant Medications. 1
- 406 References. 165-193
- 405 Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. **2011**, 1177-1191
- 404 Depressive Störungen. **2011**, 1575-1664
- 403 Development of Brain Monoaminergic Systems. **2011**, 130-151
- 402 Neurophysiological and Neuropsychological Models of Depression. **2011**, 27-56
- 401 1. Current Development of Novel Medicinal Products for Major Depressive Disorder. **2012**, 43, 131-137
- 400 Investigating Depression Severity in the Working Toward Wellness Study.
- 399 Anxiety and Depression. **2012**, 1060-1077

398 Lithium as augmentation for major depressive disorder. **2012**, 2, 15-17

397 Idiopathic Depressive Disorders: Basic Principles. 28-38

396 Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials. **2012**, 14, 2

395 Vilazodone: A landmark antidepressant approval or another fine-toothed drug?. **2013**, 3, 193-197

394 Self-rating scales. **2014**, 23-34

393 Monoamine Oxidase A and Serotonin Transporter Imaging with Positron Emission Tomography. **2014**, 711-739 1

392 A Case Demonstrating Circadian Rhythm Sleep-Wake Disorder that Was Initially Treated for Treatment-Resistant Depression. **2014**, 60, 148-153

391 Clinical relevance of vilazodone treatment in patients with major depressive disorder: categorical improvement in symptoms. **2014**, 16, 2

390 Diagnosis. **2014**, 19-29

389 Future Directions in Genetics of Psychiatric Disorders. **2014**, 311-337 0

388 Enhancing Placebo Effects in Clinical Care. **2014**, 44, 94-98

387 Pharmacogenomic testing for treatment resistant depression. **2014**, 4, 236-239

386 Long-Term, Open-Label, Safety Study of Edivoxetine as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment in Japan. **2015**, 05, 186-194

385 [Evidence-based choice and antidepressants treatment in psychiatry]. **2015**, 115, 36-42

384 Protecting the Market. **2015**, 117-133

383 Chapter 29. Psychiatry. **2015**,

382 Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder. **2015**, 4, 212279 1

381 References. **2015**, 310-326

- 380 ROLE OF L: METHYLFOLATE WITH ESCITALOPRAM FROM TREATMENT INITIATION IN DEPRESSION. **2015**, 4, 15275-15278
- 379 Shifting the Paradigm: Redefining the Treatment of Mood Disorders. **2015**, 1-3
- 378 Individualisierte Behandlungsstrategien bei depressiven Störungen. **2015**, 63, 233-238 1
- 377 Mood Disorders and Suicide. **2016**, 403-439
- 376 A Practical Outcome Evaluation Plan. **2016**, 85-88
- 375 Treatment-Resistant Depression: An Overview. **2016**, 46, 224-229 1
- 374 Brain Graph Interface. 2, e8817
- 373 Pharmacogenetics of antidepressant response: a polygenic approach.
- 372 [Genetic and clinical predictors of treatment efficacy in depressive disorders]. **2017**, 117, 55-64 1
- 371 Mood Disorders (Major Depression, Bipolar Disorder). **2017**, 1-17
- 370 SEMIPARAMETRIC REGRESSION ANALYSIS OF REPEATED CURRENT STATUS DATA. **2017**, 27, 1079-1100
- 369 Assessing Depression in the Primary Care Setting. **2017**, 10, 28-37
- 368 Mental Health. **2017**, 219-240
- 367 Major Depressive Disorder. **2017**,
- 366 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 1-5
- 365 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 467-492 1
- 364 What Outcomes Should the Study of Mental Health Try to Explain?. **2017**, 82-97 0
- 363 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, xxi-xxii

- 362 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 431-446 0
- 361 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 550-572
- 360 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 493-511 1
- 359 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 447-466
- 358 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 529-549 1
- 357 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 591-594
- 356 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 126-144
- 355 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 512-528
- 354 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 573-590
- 353 References. **2017**, 595-794
- 352 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 387-392
- 351 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 98-125
- 350 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 173-179
- 349 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, xxiii-xxvi
- 348 A Handbook for the Study of Mental Health: Social Contexts, Theories, and Systems. **2017**, 357-386 0
- 347 Mood Disorders (Major Depression, Bipolar Disorder). **2018**, 637-652
- 346 Complementary and Alternative Therapies for Treatment-Resistant Depression: A Clinical Perspective. **2018**, 123-142 1
- 345 Web-based Cognitive Behavioral Therapy Blended with Face-to-Face Sessions for Major Depression: a Randomized Clinical Trial (Preprint).

344 Statin treatment and the risk of depression.

343 Ketamine as a Rapid Antidepressant. **2019**, 139-145

2

342 Studies of the effect of cerebroprotective substances on the course of stress-induced behavioral depression. **2018**, 4, 43-48

341 The Influence of Pharmaceutical Companies and Restoring Integrity to Psychiatric Research and Practice. **2019**, 71-96

1

340 Second Courses of Transcranial Magnetic Stimulation (TMS) in Major Depressive Episodes for Initial Responders and Non-Responders. **2019**, 26, 102-109

339 Efficacy and Safety of Single Intravenous Ketamine Infusion as an Add-on to Escitalopram in Major Depression: A Randomized, Double-blind, Placebo-controlled Study. **2019**, 13, 31-36

338 Effectiveness of Text Messaging for the Management of Psychological and Somatic Distress in Depressed and Anxious Outpatients. **2019**, 12, 12-19

1

337 Neurocognitive Mechanisms for Detecting Early Phase of Depressive Disorder. **2019**, 165-198

336 Differential expression of glutamate transporters and monoaminergic genes in major depression and suicide.

0

335 Functional connectivity changes with rapid remission from moderate-to-severe major depressive disorder.

0

334 A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping.

333 Transcranial random noise stimulation for the acute treatment of depression: a randomized controlled trial.

332 Repetitive Transcranial Magnetic Stimulation With and Without Internet-Delivered Cognitive-Behavioral Therapy for the Treatment of Resistant Depression: Protocol for Patient-Centered Randomized Controlled Pilot Trial (Preprint).

331 Using data from schizophrenia outcome study to estimate the time to treatment outcome and the early-response cut-off score that predicts outcome at week 16. **2020**, 47, 65-70

1

330 The potential anti-depressant properties of dexmedetomidine infusion: a review of mechanistic, preclinical, and clinical evidence. **2020**, 31, 649-658

2

329 Convergence, preliminary findings and future directions across the four human connectome projects investigating mood and anxiety disorders. **2021**, 245, 118694

1

328 Transdiagnostic and functional predictors of depression severity and trajectory in the Penn state psychiatry clinical assessment and rating evaluation system (PCARES) registry. **2022**, 298, 86-94

0

327 Evolution and Emerging Trends in Depression Research From 2004 to 2019: A Literature Visualization Analysis. **2021**, 12, 705749

5

- 326 Sensory Stimulation Via the Visual, Auditory, Olfactory and Gustatory Systems Can Modulate Mood and Depression. **2021**, 1
- 325 Identifying factors associated with the hospital readmission rate among patients with major depressive disorder. **2021**, 21, 542 0
- 324 Treatment-Resistant Depression: Deep Brain Stimulation. **2020**, 417-432 1
- 323 Objective Assessments in Diagnoses and Treatment: A Proposed Change in Paradigm. **2021**, 52, 90-97
- 322 Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. **2022**, 297, 68-75
- 321 Unipolar depression. **2020**, 613-631
- 320 Context Matters! Depression following childbirth or a chronic disease diagnosis shows specific risk factor profiles.
- 319 Possible involvement of NO-sGC-cGMP signaling in the antidepressant like effect of pyridoxine in mice. **2021**, 1
- 318 Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study. **2021**, 41, 1055-1066
- 317 Electroacupuncture Ameliorates Depression-Like Behaviour in Rats by Enhancing Synaptic Plasticity via the GluN2B/CaMKII/CREB Signalling Pathway. **2021**, 2021, 2146001 0
- 316 Antidepressiva. **2008**, 515-553
- 315 The Author's Reply. **2008**, 26, 567-568
- 314 Monoamine Oxidase A and Serotonin Transporter Imaging with Positron Emission Tomography. **2021**, 911-942
- 313 Repetitive Transcranial Magnetic Stimulation With and Without Internet-Delivered Cognitive-Behavioral Therapy for the Treatment of Resistant Depression: Protocol for Patient-Centered Randomized Controlled Pilot Trial. **2020**, 9, e18843 3
- 312 Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder. **2021**, 41, 62-66 3
- 311 Monocyte chemoattractant protein-1 levels are associated with major depressive disorder.
- 310 Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. **2020**, 35, 1
- 309 The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks. **2007**, 32, 232-3

308	Translating evidence on depression and physical symptoms into effective clinical practice. 2007 , 9, 295-302	1
307	Validity of the bereavement exclusion criterion for the diagnosis of major depressive episode. 2007 , 6, 102-7	59
306	Agomelatine and its therapeutic potential in the depressed patient. 2007 , 3, 423-8	11
305	Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. 2009 , 6, 38-51	47
304	Do depressed patients with diabetes experience more side effects when treated with Citalopram Than their counterparts without diabetes? a STAR*D study. 2009 , 11, 186-96	
303	Treatment of depression: antidepressant monotherapy and combination therapy. 2007 , 4, 25-7	4
302	One holy grail: evidence- and measurement-based practice. 2006 , 3, 23-33	
301	Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond. 2006 , 3, 54-63	33
300	Correlation between mental health co-morbidity screening scores and clinical response in collaborative care treatment for depression. 2010 , 7, 129-33	10
299	L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode. 2011 , 8, 19-28	21
298	Biomarkers and the future of treatment for depression. 2012 , 2012, 6	5
297	Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder. 2013 , 8, 86-91	11
296	Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2016 , 16, 1-66	24
295	Residual Symptoms Were Differentially Associated with Brain Function in Remitted Patients with Major Depressive Disorders. 2016 , 59, 15-23	2
294	Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. 2013 , 16, 113-22	16
293	Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions. 2018 , 5, 36-47	14
292	The Dazzling Promise of Ketamine. 2018 , 2018,	
291	Measurement-based Care in Psychiatry-Past, Present, and Future. 2018 , 15, 13-26	34

290	Effect of Standardized Fractions and Tiliroside from Leaves of on Depression Tests in Mice. 2019 , 18, 1931-1946	2
289	A Social Media Study on the Effects of Psychiatric Medication Use. 2019 , 13, 440-451	8
288	Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury: Clinical Practice Guideline for Healthcare Providers. 2021 , 27, 152-224	2
287	A primary care first (PCP-first) model to screen and treat depression: A VitalSign report from a second cohort of 32,106 patients. 2021 , 74, 1-8	0
286	The antidepressant-like effect of resolvin E1 in repeated prednisolone-induced depression model mice. 2022 , 418, 113676	0
285	Antidepressant Like Effect of Ascorbic Acid in Mice: Possible Involvement of NO-sGC-cGMP Signaling. 2021 , 1	0
284	Exogenous Carbon Monoxide Produces Rapid Antidepressant- and Anxiolytic-Like Effects. 2021 , 12, 757417	3
283	Post-weaning Social Isolated Flinders Sensitive Line Rats Display Bio-Behavioural Manifestations Resistant to Fluoxetine: A Model of Treatment-Resistant Depression. 2021 , 12, 688150	1
282	Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness. 2021 , 27, 448-452	
281	Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy from a Phase 2B Study of Seltorexant. 2021 ,	0
280	Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. 2021 , 239, 15	4
279	Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. 2021 ,	0
278	Bifidobacterium breve CCFM1025 Attenuates Major Depression Disorder via Regulating Gut Microbiome and Tryptophan Metabolism: A Randomized Clinical Trial. 2021 , 100, 233-233	7
277	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. 2021 ,	0
276	Bibliographie. 2010 , 323-360	
275	Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice.. 2021 , 12, 469-481	1
274	The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.. 2021 , 299, 335-343	
273	Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.. 2021 , 146, 172-178	0

272	Treatment of anxiety symptoms in patients receiving rTMS for treatment resistant depression. 2022 , 2, 100014	1
271	Mechanisms of Ketamine and its Metabolites as Antidepressants.. 2021 , 114892	7
270	Daily steps and depressive symptoms: A longitudinal evaluation of patients with major depressive disorder in the precision medicine in mental health care study.. 2022 , 300, 334-340	0
269	Chapitre 2. Dépression unipolaire majeure: définition, prévalence, incidence, évolution et traitement. 2015 , 14-23	
268	Characterization of Ultrasound Neurostimulation in Mice. 2020 ,	0
267	Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. 2021 , 1	1
266	Ultrasound Neurostimulation in Mice: Impact of Ultrasound Settings and Beam Properties.. 2022 , PP,	1
265	Esketamine for treatment-resistant depression in adults. 2022 , 2022,	
264	Hydroxysafflor yellow A can improve depressive behavior by inhibiting hippocampal inflammation and oxidative stress through regulating HPA axis. 2022 , 47, 1	1
263	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A CAN-BIND Study.. 2022 ,	
262	Assessing Depressive Symptoms in Patients With Cancer Treated With Interleukin-2: A Comparison of 2 Measures.. 2022 ,	
261	Relationship Between Postnatal Depression of Mental Health Patients and the Psychological Health of Their Offspring.. 2021 , 12, 772744	
260	A novel peripheral biomarker for depression and antidepressant response.. 2022 ,	3
259	7T ultra-high-field neuroimaging for mental health: an emerging tool for precision psychiatry?. 2022 , 12, 36	0
258	Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress.. 2022 , 239, 297-311	2
257	Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Women.. 2021 , 12, 797577	1
256	Antidepressant response and stress resilience are promoted by CART peptides in GABAergic neurons of the anterior cingulate cortex. 2022 ,	1
255	A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.. 2022 , 1-25	0

254	Escitalopram Administration, Relearning, and Neuroplastic Effects: A Diffusion Tensor Imaging Study in Healthy Individuals.. 2022 , 301, 426-426	1
253	Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.. 2022 , 434, 120152	0
252	Combination of Spontaneous Regional Brain Activity and HTR1A/1B DNA Methylation to Predict Early Responses to Antidepressant Treatments in MDD.. 2022 , 302, 249-249	0
251	Translational Neuropsychopharmacology for Major Depression: Targeting Neurotransmitter Systems. 2022 , 327-334	
250	The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: a systematic review.. 2022 ,	2
249	A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression.. 2022 , 12,	4
248	Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.. 2022 , 10,	2
247	Corticomotor Plasticity as a Predictor of Response to High Frequency Transcranial Magnetic Stimulation Treatment for Major Depressive Disorder.. 2022 ,	1
246	Telemental Health Collaborative Care Medication Management: Implementation and Outcomes.. 2021 ,	
245	Validation of Machine Learning-Based Individualized Treatment for Depressive Disorder Using Target Trial Emulation.. 2021 , 11,	0
244	The effect of fluoxetine combined with repetitive transcranial magnetic stimulation on the psychological emotions and cognitive and neurological functions of acute post-stroke depression patients. 2021 , 13, 11883-11889	
243	[Current methods for predicting therapeutic response in patients with depressive disorders].. 2022 , 122, 15-21	0
242	Depression and epigenetics: Epidemiology, pathophysiology, diagnosis, and assessment. 2022 , 51-65	
241	Depression management and pharmacoeigenetics. 2022 , 67-84	
240	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.. 2022 , 36, 151-158	14
239	Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study.. 2022 , 12,	1
238	Repeated Yueju, But Not Fluoxetine, Induced Sustained Antidepressant Activity in a Mouse Model of Chronic Learned Helplessness: Involvement of CaMKII Signaling in the Hippocampus.. 2022 , 2022, 1442578	0
237	Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): recruitment, retention, and data availability in a longitudinal remote measurement study.. 2022 , 22, 136	2

- 236 Lower Levels of GABAergic Function Markers in Corticotropin-Releasing Hormone-Expressing Neurons in the sgACC of Human Subjects With Depression.. **2022**, 13, 827972
- 235 Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder.. **2022**, 16, 831278 0
- 234 Integrative Functional, Molecular, and Transcriptomic Analyses of Altered Intrinsic Timescale Gradient in Depression.. **2022**, 16, 826609 0
- 233 Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.. **2022**, 1 1
- 232 Developing symptom clusters: linking inflammatory biomarkers to depressive symptom profiles.. **2022**, 12, 133 0
- 231 The role of serotonin neurotransmission in rapid antidepressant actions.. **2022**, 1 0
- 230 Effects of an immersive psychosocial training program on depression and well-being: A randomized clinical trial.. **2022**, 150, 292-299
- 229 High Yielding Continuous-Flow Synthesis of Norketamine.. **2022**, 26, 1145-1151 0
- 228 The Role of MicroRNA and Microbiota in Depression and Anxiety.. **2022**, 16, 828258 0
- 227 Similar Outcomes in Treating Major Depressive Disorder With 10 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Intermittent Theta Burst Stimulation (iTBS): A Naturalistic Observational Study.. **2022**, 28, 98-107 0
- 226 Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts.. **2022**, 13, 824919
- 225 A Chinese adaptation of six items, self-report Hamilton Depression Scale: Factor structure and psychometric properties.. **2022**, 73, 103104 0
- 224 A psychobiotic approach to the treatment of depression: A systematic review and meta-analysis. **2022**, 91, 104999 2
- 223 Is (R)-ketamine a Potential Therapeutic Agent for Treatment-Resistant Depression with Less Detrimental Side Effects? A Review of Molecular Mechanisms Underlying Ketamine and its Enantiomers.. **2022**, 114963 0
- 222 Reinforcement Learning in Patients With Mood and Anxiety Disorders vs Control Individuals: A Systematic Review and Meta-analysis.. **2022**, 3
- 221 Does the evidence support a relationship between higher levels of nut consumption, lower risk of depression, and better mood state in the general population? A systematic review.. **2022**, 0
- 220 Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response. **2022**, 0
- 219 Cognitive behavioral therapy may rehabilitate abnormally functional communication pattern among the triple-network in major depressive disorder: A follow-up study.. **2022**, 304, 28-39 1

218	Pragmatic implementation of the Clinical Global Impression Scale of Severity as a tool for measurement-based care in a first-episode psychosis program.. 2022 , 243, 147-153	0
217	Childhood adversity and adulthood major depressive disorder.. 2022 , 76, 36-44	1
216	Measurement Based Care in a first episode psychosis program: Development of an algorithm of care based on the Clinical Global Impressions Scale.. 2022 , 150, 8-16	
215	Update on Statin Treatment in Patients with Neuropsychiatric Disorders.. 2021 , 11,	2
214	Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.. 2021 , 22, 919	0
213	P.0695 The influence of baseline functioning on life engagement outcomes: post hoc analysis of three brexpiprazole studies in major depressive disorder. 2021 , 53, S509	
212	Sortilin deletion in the prefrontal cortex and hippocampus ameliorates depressive-like behaviors in mice via regulating ASM/ceramide signaling.. 2021 ,	1
211	Influence of functional gene polymorphisms on human behaviour: the case of .. 2021 , 46, E659-E662	
210	Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression.. 2021 , 12, 762738	8
209	Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders.. 2021 , 11, 24226	0
208	Is transcranial direct current stimulation, alone or in combination with antidepressant medications or psychotherapies, effective in treating major depressive disorder? A systematic review and meta-analysis.. 2021 , 19, 319	1
207	Depression and Anxiety Disorders. 305-450	
206	ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. 2021 ,	2
205	Burnout and Moral Injury Among Consultation-Liaison Psychiatry Trainees. 2021 , 49, 543-561	
204	Treatment-resistant depression: therapeutic options when first-line treatments fail. 2022 , 28, 4-8	
203	Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research.. 2021 , 12, 792960	3
202	Pathomechanisms of Vascular Depression in Older Adults.. 2021 , 23,	4
201	Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study.. 2021 , 12, 801738	

200 Isobolographic analysis of the antidepressant interaction in two-drug combinations of citalopram, bupropion, and scopolamine in mice.. **2022**, 1

199 Evaluation of a gallery-based Arts Engagement program for depression. 1-11 ○

198 Estrogen, the Peripheral Immune System and Major Depression - A Reproductive Lifespan Perspective.. **2022**, 16, 850623 ○

197 Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.. **2022**, 13, 884213

196 Anesthetic considerations in psychiatric diseases. 83-87

195 DataSheet_1.pdf. **2020**,

194 Table_2.xlsx. **2020**,

193 Table_1.docx. **2020**,

192 Table_1.DOCX. **2018**,

191 Table_2.DOCX. **2018**,

190 Table_3.DOCX. **2018**,

189 Table_1.DOCX. **2018**,

188 Table_1.docx. **2020**,

187 Data_Sheet_1.docx. **2019**,

186 Data_Sheet_2.docx. **2019**,

185 Data_Sheet_1.pdf. **2020**,

184 Data_Sheet_1.docx. **2019**,

183 Table_1.xlsx. **2020**,

182	Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury. 2021 , 27, 152-224	2
181	Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders.. 2022 , 20, 248-258	
180	Yoga for Mental Health Disorders. 2022 , 1270-1289	
179	Synapse differentiation-induced gene 1 regulates stress-induced depression through interaction with the AMPA receptor GluA2 subunit of nucleus accumbens in male mice.. 2022 , 109076	0
178	Behavioral Activation, Depression, and Promotion of Health Behaviors: A Scoping Review.. 2022 , 10901981221090157	
177	Oral Administration of 5-Hydroxytryptophan Restores Gut Microbiota Dysbiosis in a Mouse Model of Depression.. 2022 , 13, 864571	0
176	A Possible Antidepressive Effect of Dietary Interventions: Emergent Findings and Research Challenges.. 2022 , 1-12	0
175	The burden associated with, and management of, difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom.. 2022 , 2698811221090628	0
174	Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial. 11, 510	
173	Craving and addictive potential of esketamine as side effects?. 2022 , 1-10	
172	Optimization of measurement-based care (OMBC) for depression based on all-round and continuous assessment: rationale and protocol for a multicenter randomized control clinical trial.. 2022 , 23, 367	0
171	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.. 2022 , 1-19	2
170	Changes in the amplitude of low-frequency fluctuations in specific frequency bands in major depressive disorder after electroconvulsive therapy. 2022 , 12, 708-721	
169	PLASTICITY IN MENTAL HEALTH: A NETWORK THEORY.. 2022 , 104691	0
168	Efficacy and Acceptability of Remote Cognitive Behavioral Therapy for Patients With Major Depressive Disorder in Japanese Clinical Settings: A Case Series. 2022 ,	0
167	RECENTERING NEUROSCIENCE ON BEHAVIOR:THE INTERFACE BETWEEN BRAIN AND ENVIRONMENT IS A PRIVILEGED LEVEL OF CONTROL OF NEURAL ACTIVITY.. 2022 , 104678	1
166	IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine.. 2022 , 12, 178	0
165	Predicting treatment outcome in depression: an introduction into current concepts and challenges.. 2022 ,	0

164	Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.. <i>American Journal of Psychiatry</i> , 2022 , appiajp21080800	11.9	6
163	Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study.. 2022 , 2698811221089035		1
162	The Relationship Between 5-Hydroxytryptamine and Its Metabolite Changes With Post-stroke Depression.. 2022 , 13, 871754		0
161	Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review. 2022 , 13,		1
160	Rapid-Onset Antidepressant-Like Effect of Nelumbinis semen in Social Hierarchy Stress Model of Depression. 2022 , 2022, 1-13		
159	Intermittent theta burst stimulation (iTBS) versus 10-Hz high-frequency repetitive transcranial magnetic stimulation (rTMS) to alleviate treatment-resistant unipolar depression: A randomized controlled trial (THETA-DEP). 2022 ,		1
158	Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review. 2022 , 12, 907		0
157	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. 2022 , 9, 100370		
156	Oxytocin treatment improves dexamethasone-induced depression-like symptoms associated with enhancement of hippocampal CREB-BDNF signaling in female mice.		0
155	Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults. 13,		
154	Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. 2022 , 5, e2216349		1
153	Possible involvement of NO-cGMP signaling in the antidepressant like Effect of Amantadine in mice.		
152	Contribution of the opioid system to the antidepressant effects of fluoxetine. 2022 ,		0
151	Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. 2022 , 74, 506-551		3
150	Dimensions and Predictors of Personal Recovery in Major Depression. 2022 , 225-244		
149	Measurement-Based Care (MBC): Advances in the Twenty-First Century. 2022 , 157-166		
148	Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder. 2022 , 22,		
147	Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.		1

- 146 A tale of two transmitters: serotonin and histamine as in vivo biomarkers of chronic stress in mice. **2022**, 19, 1
- 145 Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene. 13, 0
- 144 Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. **2022**, 328, 151 4
- 143 Creating sparser prediction models of treatment outcome in depression: a proof-of-concept study using simultaneous feature selection and hyperparameter tuning. **2022**, 22, 0
- 142 Psychedelic drugs for psychiatric disorders. **2022**, 440, 120332
- 141 At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. **2022**, 314, 59-67 1
- 140 Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression.
- 139 Mental Activity as the Bridge between Neural Biomarkers and Symptoms of Psychiatric Illness. 155005942211124
- 138 Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. **2022**, 20, 1
- 137 Network structure of time-varying depressive symptoms through dynamic time warp analysis in late-life depression.
- 136 The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients. **2022**, 110608
- 135 Feasibility and acceptability of a novel telepsychiatry-delivered precision prescribing intervention for anxiety and depression. **2022**, 22, 0
- 134 Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study.
- 133 Camellia nitidissima Chi extract promotes adult hippocampal neurogenesis and attenuates chronic corticosterone-induced depressive behaviours through regulating Akt/GSK3 β /CREB signaling pathway. **2022**, 95, 105199
- 132 Copyright Page. **2006**, iv-iv
- 131 Preface. **2006**, vii-viii
- 130 Dedication. **2006**, v-vi
- 129 SUMOylation and Major Depressive Disorder. **2022**, 23, 8023 0

- 128 Loureirin C and Xanthoceraside Prevent Abnormal Behaviors Associated with Downregulation of Brain Derived Neurotrophic Factor and AKT/mTOR/CREB Signaling in the Prefrontal Cortex Induced by Chronic Corticosterone Exposure in Mice. 1
- 127 Dopamine dysfunction in depression: application of texture analysis to dopamine transporter single-photon emission computed tomography imaging. **2022**, 12, 1
- 126 Assessment of objective and subjective cognitive function in patients with treatment-resistant depression undergoing repeated ketamine infusions. 0
- 125 Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants. **2022**, 10, 1947
- 124 Experiences of treatment-resistant mental health conditions in primary care: a systematic review and thematic synthesis. **2022**, 23, 0
- 123 Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder. 1-18 0
- 122 Salt-inducible kinase 1-CREB-regulated transcription coactivator 1 signalling in the paraventricular nucleus of the hypothalamus plays a role in depression by regulating the hypothalamic-pituitary-adrenal axis.
- 121 A Single Index Model for Longitudinal Outcomes to Optimize Individual Treatment Decision Rules.
- 120 Depression: As a Risk Factor for Coronary Heart Disease. **2022**, 139-145
- 119 Baseline cognitive functioning can predict the trajectory of acute treatment in first-episode major depressive disorder. 0
- 118 Bipolar disorder predicted shorter and borderline personality disorder symptoms longer time to remission | A prospective cohort study of major depressive patients. **2022**, 316, 161-168 0
- 117 Emerging drugs for the treatment of major depressive disorder. 1-13 0
- 116 The role of reelin in the pathological mechanism of depression from clinical to rodents. **2022**, 317, 114838 0
- 115 Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study. **2022**, 318, 331-337 0
- 114 Precision Medicine in Psychiatric Disorders. **2022**, 93-112 0
- 113 EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder. **2022**, 1-11 0
- 112 Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China. 13, 0
- 111 Modulation of resting-state functional connectivity in default mode network is associated with the long-term treatment outcome in major depressive disorder. 1-13 0

110	Persistent ventral anterior cingulate cortex and resolved amygdala hyper-responses to negative outcomes after depression remission: a combined cross-sectional and longitudinal study. 2022,	0
109	Outcomes associated with antidepressant treatment according to the number of prescriptions and treatment changes: 5-year follow-up of a nation-wide cohort study. 13,	0
108	Effects of GRIN2B, GRIA1, and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial. Publish Ahead of Print,	0
107	Telehealth-Supported Decision-making Psychiatric Care for Suicidal Ideation: Longitudinal Observational Study. 2022, 6, e37746	0
106	NUDT6, the Antisense Protein of FGF2 Gene, Plays a Depressogenic Role by Promoting Inflammation and Suppressing Neurogenesis without Altering FGF2 Signaling.	0
105	Enhanced Adoption of Measurement-Based Care in a Psychiatry Outpatient Clinic After High-Reliability Process Changes.	0
104	Therapeutic potential of Polygala saponins in neurological diseases. 2022, 154483	0
103	Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. 2022, 8,	1
102	The effect of the time to remission on residual symptoms and functioning among depressive patients. 2022,	0
101	Insulin modulates emotional behavior through a serotonin-dependent mechanism.	0
100	Emulating a target trial of dynamic treatment strategies for major depressive disorder using data from the STAR*D randomized trial. 2022,	0
99	Risk factor profiles for depression following childbirth or a chronic disease diagnosis: case-control study. 2022, 8,	1
98	Synthesis and antidepressant activity of novel 1-(1-benzoylpiperidin-4-yl) methanamine derivatives selectively targeting SSRI/5-HT1A. 2022, 76, 129006	0
97	Alteration in NMDAR subunits in different brain regions of chronic unpredictable mild stress (CUMS) rat model. 2022, 13, 379-389	0
96	The Antidepressant Advisor (ADeSS): A Decision Support System for Antidepressant Treatment for Depression in UK primary care: a feasibility study.	0
95	Resolution of depression: Antidepressant actions of resolvins. 2022,	1
94	Real-world observation on response to cholinesterase inhibitors or selective serotonin reuptake inhibitors prescribed to outpatients with dementia using electronic medical records.	0
93	Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. 2022,	0

92	The role of exercise in the treatment of depression: biological underpinnings and clinical outcomes.	1
91	The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients. 13,	0
90	Ketamine and its metabolites: Potential as novel treatments for depression. 2022 , 109305	2
89	Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders. 2022 , 19, 866-871	0
88	Examining the synergistic effects of a cognitive control video game and a home-based, self-administered non-invasive brain stimulation on alleviating depression: the DiSCoVeR trial protocol.	0
87	Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population. 2022 ,	0
86	Clinical utility of pharmacogenetics in a psychiatric and primary care population.	0
85	Interactive Effects of Serum Leptin Levels and Physical Comorbidity on the Pharmacotherapeutic Response of Depressive Disorders. 2022 , 20, 662-674	0
84	A Scoping Review of Measures Used in Early Intervention Services for Psychosis.	0
83	Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. 2023 , 320, 353-359	1
82	Changes of anhedonia and cognitive symptoms in first episode of depression and recurrent depression, an analysis of data from NSSD. 2023 , 321, 47-55	0
81	Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants. 2023 , 223, 109325	0
80	Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study. 2022 , 12,	1
79	Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine. 2023 , 224, 109335	0
78	A Viewpoint on Aldosterone and BMI Related Brain Morphology in Relation to Treatment Outcome in Patients with Major Depression.	0
77	NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. 2023 , 225, 109378	1
76	Exploring the multifocal role of phytoconstituents as antidepressants. 2023 , 123, 110693	0
75	Positive anxiety or depression screen despite ongoing antidepressant prescription in people with epilepsy: A large cross-sectional analysis. 2022 , 20, 100572	0

74	Effect of Personality Traits on Sustained Remission Among Patients with Major Depression: A 12-Month Prospective Study. Volume 18, 2771-2781	○
73	Integrated Module of Multidimensional Omics for Peripheral Biomarkers (iMORE) in patients with major depressive disorder: rationale and design of a prospective multicentre cohort study. 2022 , 12, e067447	○
72	The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. 2022 , 22,	○
71	Salt-inducible kinase 1-CREB-regulated transcription coactivator 1 signalling in the paraventricular nucleus of the hypothalamus plays a role in depression by regulating the hypothalamic-pituitary-adrenal axis.	○
70	QEEG Predictors of Treatment Response in Major Depressive Disorder- A Replication Study from Northwest India. 155005942211423	○
69	The clinical & economic burden of treatment-resistant depression in the Gulf-Cooperation Council: The Kingdom of Saudi Arabia, Kuwait and the United Arab Emirates.	○
68	Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?.	○
67	On-Line Therapist Training on Prolonged Grief Disorder Therapy: A Pilot Study (Preprint).	○
66	Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo.	○
65	ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice. 2022 , 12,	○
64	Using filled prescription sequences to rank antidepressants: A nationwide replication study. 2022 ,	○
63	Dopamine, Immunity and Disease. PHARMREV-AR-2022-000618	1
62	TED Trazodone Efficacy in Depression: A Naturalistic Study on the Efficacy of Trazodone in an Extended-Release Formulation Compared to SSRIs in Patients with a Depressive Episode Preliminary Report. 2023 , 13, 86	○
61	A paradigm shift in translational psychiatry through rodent neuroethology.	○
60	A transdiagnostic network for psychiatric illness derived from atrophy and lesions.	○
59	Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex.	○
58	Integration of a pharmacist-led pharmacogenomic service in a geriatric clinic: Barriers and outcomes. 2023 ,	○
57	Exposure to enriched environment ameliorated chronic unpredictable mild stress-induced depression-like symptoms in rats via regulating the miR-92a-3p/kruppel-like factor 2 (KLF2) pathway. 2023 ,	○

- 56 Early Response to Antidepressant Medications in Adults With Major Depressive Disorder. **2023**, 43, 46-54 ○
- 55 Necroptotic kinases are involved in the reduction of depression-induced astrocytes and fluoxetine's inhibitory effects on necroptotic kinases. 13, ○
- 54 Add-On Intermittent Theta Burst Stimulation Improves the Efficacy of First-Episode and Recurrent Major Depressive Disorder: Real-World Clinical Practice. Volume 19, 109-116 ○
- 53 The experience of treatment-resistant depression: A qualitative meta-synthesis. ○
- 52 The Precision in Psychiatry (PIP) study: Testing an internet-based methodology for accelerating research in treatment prediction and personalisation. **2023**, 23, ○
- 51 Oral Ketamine for Depression: An Updated Systematic Review. 1-36 ○
- 50 A Novel Approach to Measurement-Based Care: Integrating Palliative Care Tools Into Geriatric Mental Health. 104990912211502 ○
- 49 Temporal multi-step predictive modeling of remission in major depressive disorder using early stage treatment data; STAR*D based machine learning approach. **2023**, 324, 286-293 ○
- 48 Relationship between daily rated depression symptom severity and the retrospective self-report on PHQ-9: A prospective ecological momentary assessment study on 80 psychiatric outpatients. **2023**, 324, 170-174 ○
- 47 White matter integrity and pro-inflammatory cytokines as predictors of antidepressant response in MDD. **2023**, 159, 22-32 ○
- 46 Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. **2023**, 226, 109422 ○
- 45 Psilocybin for Depression: From Credibility to Feasibility, What's Missing?. **2023**, 16, 68 ○
- 44 Recent advances in low-level laser therapy on depression. **2022**, 1-16 ○
- 43 Phytochemicals That Act on Synaptic Plasticity as Potential Prophylaxis against Stress-Induced Depressive Disorder. **2023**, ○
- 42 Personalized symptom clusters that predict depression treatment outcomes: A replication of machine learning methods. **2023**, 11, 100470 ○
- 41 Feasibility of performing a multi-arm clinical trial examining the novel combination of repetitive transcranial magnetic stimulation and aerobic exercise for post-stroke depression. 1-14 ○
- 40 Tissue-specific oxysterols as predictors of antidepressant (escitalopram) treatment response in patients with major depressive disorder. **2023**, ○
- 39 ABCB1 gene variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-analysis including results from the CAN-BIND -1 Study. ○

- 38 AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale. **2023**, 23, ○
- 37 The Change of Suicidal Ideation Over a 12-Week Naturalistic Treatment of Depression: Comparison Between Young People and Older Adults. **2023**, 20, 9-17 ○
- 36 Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review. **2023**, 16, 568 ○
- 35 Altered neurotransmission in stress-induced depressive disorders: The underlying role of the amygdala in depression. **2023**, 98, 102322 ○
- 34 Right-side frontal-central cortical hyperactivation before the treatment predicts outcomes of antidepressant and electroconvulsive therapy responsivity in major depressive disorder. **2023**, 161, 377-385 ○
- 33 Nucleus accumbens in the pathogenesis of major depressive disorder: A brief review. **2023**, 196, 68-75 ○
- 32 Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis. **2023**, 324, 115179 ○
- 31 Outcomes for treatment of depression in the Veterans Health Administration: Rates of response and remission calculated from clinical and survey data. **2023**, 324, 115196 ○
- 30 Playing with a full dex of cards: Treatment resistant depression with suicidality responds to inpatient dextromethorphan therapy. **2023**, 2, 100105 ○
- 29 Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages. **2023**, 12, 942 ○
- 28 A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder. **2023**, 447, 114431 ○
- 27 Systematic review of structured care pathways in major depressive disorder and bipolar disorder. **2023**, 23, ○
- 26 Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder. 17, ○
- 25 A Web-Based Therapist Training Tutorial on Prolonged Grief Disorder Therapy: Pre-Post Assessment Study. 9, e44246 ○
- 24 Organic cation transporter 2 contributes to SSRI antidepressant efficacy by controlling tryptophan availability in the brain. ○
- 23 Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. **2023**, 180, 241-251 2
- 22 Educating Mental Health Trainees About Measurement-Based Care: A Scoping Review. **2023**, 47, 187-195 ○
- 21 Resting-state functional connectivity of the raphe nuclei in major depressive Disorder: A Multi-site study. **2023**, 37, 103359 ○

- 20 Lipopolysaccharide-binding protein expression is increased by stress and inhibits monoamine synthesis to promote depressive symptoms. **2023**, 56, 620-634.e11 ○
- 19 Ursachen von therapieresistenter Depression: Persönlichkeitsstruktur und psychosoziale Faktoren. **2022**, 47-66 ○
- 18 Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. **2023**, 180, 190-199 1
- 17 Genetics of antidepressant response and treatment-resistant depression. **2023**, ○
- 16 Serum angioneurin levels following electroconvulsive therapy for mood disorders. ○
- 15 A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China. **2023**, 37, ○
- 14 Environmental enrichment promotes resilience to neuropathic pain-induced depression and correlates with decreased excitability of the anterior cingulate cortex. 17, ○
- 13 Repetitive transcranial magnetic stimulation for post-stroke depression: An overview of systematic reviews. 14, ○
- 12 A double-hit of social and economic stress in mice precipitates changes in decision-making strategies. ○
- 11 Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface. **2023**, 435-458 ○
- 10 Efficacy and safety of theta burst versus repetitive transcranial magnetic stimulation for major depressive disorder: a meta-analysis of randomized controlled trials. ○
- 9 Improving Identification and Treatment Outcomes of Treatment-Resistant Depression Through Measurement-Based Care. **2023**, ○
- 8 Pharmacotherapy for Treatment-Resistant Depression. **2023**, ○
- 7 Approach to Diagnosis and Management of Treatment-Resistant Depression. **2023**, ○
- 6 Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders. Volume 19, 811-828 ○
- 5 Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis. **2023**, 13, 1043 ○
- 4 Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder. 14, ○
- 3 Letter to the editor: reflections on the future of medical cannabis research for depression. 1-2 ○

2 Connecting Dots between Mitochondrial Dysfunction and Depression. **2023**, 13, 695 ○

1 A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. 026988112311678 ○